WO2000031239A1 - Immune cells having predefined biological specificity, comprising chimeric t cell receptor - Google Patents
Immune cells having predefined biological specificity, comprising chimeric t cell receptor Download PDFInfo
- Publication number
- WO2000031239A1 WO2000031239A1 PCT/IL1999/000622 IL9900622W WO0031239A1 WO 2000031239 A1 WO2000031239 A1 WO 2000031239A1 IL 9900622 W IL9900622 W IL 9900622W WO 0031239 A1 WO0031239 A1 WO 0031239A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tcr
- antigen
- immune cell
- cells
- specific
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 130
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 14
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 243
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 224
- 239000000427 antigen Substances 0.000 claims abstract description 140
- 210000004027 cell Anatomy 0.000 claims abstract description 138
- 108091007433 antigens Proteins 0.000 claims abstract description 135
- 102000036639 antigens Human genes 0.000 claims abstract description 135
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 44
- 239000012634 fragment Substances 0.000 claims abstract description 35
- 230000002463 transducing effect Effects 0.000 claims abstract description 29
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 8
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 6
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 5
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 claims abstract description 3
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 claims abstract description 3
- 230000000536 complexating effect Effects 0.000 claims abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 108
- 108090000623 proteins and genes Proteins 0.000 claims description 71
- 201000001441 melanoma Diseases 0.000 claims description 42
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 19
- 210000004698 lymphocyte Anatomy 0.000 claims description 18
- 102000005962 receptors Human genes 0.000 claims description 18
- 108020003175 receptors Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 230000011664 signaling Effects 0.000 claims description 14
- 108010087819 Fc receptors Proteins 0.000 claims description 12
- 102000009109 Fc receptors Human genes 0.000 claims description 12
- 210000002540 macrophage Anatomy 0.000 claims description 12
- 210000001616 monocyte Anatomy 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 10
- 210000000822 natural killer cell Anatomy 0.000 claims description 10
- 230000002147 killing effect Effects 0.000 claims description 9
- 230000006870 function Effects 0.000 claims description 8
- 210000004180 plasmocyte Anatomy 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 7
- 230000003013 cytotoxicity Effects 0.000 claims description 7
- 231100000135 cytotoxicity Toxicity 0.000 claims description 7
- 230000004069 differentiation Effects 0.000 claims description 7
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 108091008042 inhibitory receptors Proteins 0.000 claims description 5
- 230000004068 intracellular signaling Effects 0.000 claims description 5
- 230000001613 neoplastic effect Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 231100000617 superantigen Toxicity 0.000 claims description 5
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 4
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 4
- 230000030741 antigen processing and presentation Effects 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 230000016396 cytokine production Effects 0.000 claims description 4
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000003979 eosinophil Anatomy 0.000 claims description 3
- 230000016784 immunoglobulin production Effects 0.000 claims description 3
- 229920002521 macromolecule Polymers 0.000 claims description 3
- 108090001008 Avidin Proteins 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 2
- 230000000284 resting effect Effects 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 47
- 230000001177 retroviral effect Effects 0.000 description 34
- 239000013598 vector Substances 0.000 description 34
- 239000013615 primer Substances 0.000 description 27
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 17
- 238000004806 packaging method and process Methods 0.000 description 16
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 15
- 238000010367 cloning Methods 0.000 description 15
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 14
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 13
- 238000010276 construction Methods 0.000 description 13
- 210000004962 mammalian cell Anatomy 0.000 description 10
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 10
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000009258 tissue cross reactivity Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000002752 melanocyte Anatomy 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 102000011931 Nucleoproteins Human genes 0.000 description 5
- 108010061100 Nucleoproteins Proteins 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 241001500351 Influenzavirus A Species 0.000 description 4
- 101150117115 V gene Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091071247 Beta family Proteins 0.000 description 2
- 101150082143 CD24 gene Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012411 cloning technique Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008957 viral persistence Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
Definitions
- the present invention relates generally to the fields of immunology and molecular cell biology. More specifically, the present invention relates to immune cells complexed with a chimeric T cell receptor (TCR) or a fragment thereof, or transfected with a chimeric TCR gene.
- TCR chimeric T cell receptor
- the immune response is a complex defense system able to recognize and kill invading organisms, e.g., bacteria, viruses, fungi, allogeneic tissue and some types of tumor cells.
- the characteristic aspects of the immune system are the specific recognition of antigens, the ability to discriminate between self and non-self antigens and a "memory" which enables a quick, specific reaction to previously encountered antigens.
- the immune system in mammals reacts to antigens via both humoral and cell-mediated immune responses.
- the major pathway of the immune defense begins with the trapping of the antigen by accessory cells such as dendritic cells or macrophages with subsequent concentration in lymphoid organs.
- accessory cells such as dendritic cells or macrophages with subsequent concentration in lymphoid organs.
- mature T helper cells can be triggered to become activated T helper cells.
- activated T helper cells regulate both the humoral immune response by inducing the differentiation of B cells to antibody-producing plasma cells and control of cell-mediated immune response by activation of cytotoxic T lymphocytic (CTL) cells and natural killer (NK) cells.
- CTL cytotoxic T lymphocytic
- NK natural killer
- T lymphocytes recognize antigen in the context of self Major Histocompatibility Complex (MHC) molecules by means of the T cell receptor (TCR).
- TCR T cell receptor
- the TCR expressed on the surface of T cells is a disulfide-linked heterodimer non-covalently associated with an invariant structure, the CD3 complex.
- CD3 is assumed to be responsible for intracellular signalling following occupancy of the TCR by ligand.
- Most T cells carry TCRs consisting of a and ⁇ glycoproteins ( ⁇ and ⁇ chains of the TCR), while some T cells carry TCRs having ⁇ and ⁇ glycoproteins ( ⁇ and ⁇ chains).
- the TCR genes are composed of variable segments which rearrange during T cell development.
- TCR like Ig polypeptides, consist of amino terminal variable (N) and carboxyl terminal constant (C) regions.
- the variable region V is responsible for the specific recognition of antigen whereas the constant C region functions in membrane anchoring and in transmitting of the signal that the receptor is occupied, from the outside to the inside of the cell.
- the variable regions of the Ig heavy chain and the TCR ⁇ chain are encoded by three gene segments, the variable (V), diversity (D) and joining (J) segments.
- the Ig light chain and the TCR ⁇ chain contain variable regions encoded by N and J segments.
- T cell receptor for antigen-CD3 complex recognizes antigenic peptides that are presented to it by the MHC proteins. Complexes of MHC and peptide are expressed on the surface of antigen presenting cells and other T cell targets. Stimulation of the TCR/CD3 complex results in activation of the T cell and a consequent antigen-specific immune response.
- the TCR/CD3 complex plays a central role in the effector function and regulation of the immune system. Two forms of T cell receptor for antigen are expressed on the surface of T cells.
- each of these chains is made of the V and C regions of the TCR, namely N ⁇ C ⁇ , V « C selfish , V C , and
- NgCg .T cells are capable of rearranging the genes that encode the ⁇ , ⁇ , ⁇ and 5 chains of the T cell receptor.
- T cell receptor gene rearrangements are analogous to those that produce functional immunoglobulins in B cells and the presence of multiple variable and joining regions in the genome allows the generation of T cell receptors with a diverse range of binding specificities.
- Each ⁇ / ⁇ or ⁇ / heterodimer is expressed on the surface of the T cell in association with four invariant peptides. These are the ⁇ , ⁇ and ⁇ subunits of the CD3 complex and the zeta chain.
- the CD3 ⁇ , and ⁇ polypeptides are encoded by three members of the immunoglobulin supergene family and are found in a cluster on human chromosome 11 or murine chromosome 9.
- the zeta chain gene is found separately from other TCR and CD3 genes on chromosome 1 in both the mouse and human.
- CD3 chains and the zeta subunit do not show variability, and are not involved directly in antigen recognition.
- All the components of the T cell receptor are membrane proteins and consist of a leader sequence, externally-disposed ⁇ -terminal extracellular domains, a single membrane-spanning domain, and cytoplasmic tails.
- the ⁇ , ⁇ , ⁇ and ⁇ antigen-binding polypeptides are glycoproteins.
- the zeta chain hasa relatively short ectodomain of only nine amino acids and a long cytoplasmic tail of approximately 110 amino acids.
- Most T cell receptor ⁇ / ⁇ heterodimers are covalently linked through disulphide bonds, but many ⁇ / ⁇ receptors associate with one another non-covalently.
- the zeta chain quantitatively forms either disulphide-linked ⁇ - ⁇ heterodimers or zeta-zeta homodimers.
- Fc receptor Another example of a type of receptor on cells of the immune system is the Fc receptor.
- effector functions such as antibody-dependent cytotoxicity, mast cell degranulation, and phagocytosis to immunomodulatory signals such as regulating lymphocyte proliferation, phagocytosis and target cell lysis. All these interactions are initiated through the binding of the Fc domain of antibodies or immune complexes to specialized cell surface receptors on hematopoietic cells.
- FcRs structural heterogeneity of Fc receptors
- FcRs are defined by their specificity for immunoglobulin isotypes.
- Fc receptors for IgG are referred to as Fc ⁇ R, for IgE as Fc ⁇ R, for IgA as Fc ⁇ R, etc.
- Structurally distinct receptors are distinguished by a Roman numeral, based on historical precedent.
- Fc ⁇ RI, Fc ⁇ RII and Fc ⁇ Ri ⁇ Two groups of Fc ⁇ R have been defined; these are referred to as Fc ⁇ RI and FcgRQ. Structurally related although distinct genes within a group are denoted by A, B, C.
- the protein subunit is given a Greek letter, such as Fc ⁇ RIIIA ⁇ , Fc ⁇ RIIIA ⁇ .
- All the CD3 chains ( ⁇ , ⁇ , ⁇ , ⁇ and ⁇ ) and the FcR- ⁇ chain contain Immunoreceptor Tyrosine Activation Motifs (ITAMs) which undergo phosphorilation and is responsible for the signal transduction of the cells.
- ITAMs Immunoreceptor Tyrosine Activation Motifs
- the low affinity receptor for IgG (Fc ⁇ RIHA), is composed of the ligand binding
- the CD16 polypeptide appears as membrane anchored form in polymorphonuclear cells and as transmembrane form (CD16 TM ) in NK cells.
- the FoyRDIA serves as a triggering molecule for NK cells.
- IL-2 receptor Another type of immune cell receptor is the IL-2 receptor. This receptor is composed of three chains, the ⁇ chain (p55), the ⁇ chain (pi 5) and the ⁇ chain. When stimulated by IL-2, lymphocytes undergo proliferation and activation.
- Antigen-specific effector lymphocytes such as tumor specific T cells (Tc) are very rare, individual-specific, limited in their recognition spectrum and difficult to obtain against most malignancies. Antibodies, on the other hand, are readily obtainable, more easily derived, have wider spectrum and are not individual-specific.
- the major problem of applying specific antibodies for cancer immunotherapy lies in the inability of sufficient amounts of monoclonal antibodies (mAb) to reach large areas within solid tumors. In practice, many clinical attempts to recruit the humoral or cellular arms of the immune system for passive anti-tumor immunotherapy have not fulfilled expectations. While it has been possible to obtain anti-tumor antibodies, their therapeutic use has been limited so far to blood-borne tumors primarily because solid tumors are inaccessible to sufficient amounts of antibodies.
- effector lymphocytes in adoptive immunotherapy, although effective in selected solid tumors, suffers on the other hand, from a lack of specificity (such as in the case of lymphokine-activated killer cells (LAK cells) which are mainly NK cells) or from the difficulty in recruiting tumor-infiltrating lymphocytes (TILs) and expanding such specific T cells for most malignancies.
- LAK cells lymphokine-activated killer cells
- TILs tumor-infiltrating lymphocytes
- PCT WO/94/29438 describes a method for transducing mammalian target cells with foreign genes, e.g. a gene encoding a chimeric T cell receptor, comprising transient cotransfection of a first population of mammalian cells that can produce virus with a retroviral packaging plasmid and a retroviral vector encoding a foreign gene, and cocultivation of said first population of mammalian cells producing replication-defective recombinant retroviral vectors carrying said foreign gene with a second population of mammalian target cells to transduce said second population of target cells with said foreign gene.
- the TCR contains a non-MHC restricted extracellular surface membrane protein domain binding specifically to at least one ligand.
- It is an object of the present invention is to endow immune cells with a predefined specificity by grafting immune cells with chimeric TCR specificity.
- the present invention relates to an immune cell having predefined specificity, wherein said immune cell is either complexed with an antigen-specific MHC-restricted chimeric T cell receptor (TCR) or a fragment thereof, or is transfected with an antigen-specific MHC-restricted chimeric TCR gene.
- TCR antigen-specific MHC-restricted chimeric T cell receptor
- the immune cell is complexed with the TCR or TCR fragment by chemical conjugation.
- the TCR or TCR fragment may also be bridged to the immune cell by a macromolecule linker such as, but not being limited to, avidin, streptavidin or poly ly sine, or by a bispecific antibody that binds both to the TCR or TCR fragment and to the immune cell.
- the immune cell is transfected with a chimeric TCR gene or a DNA sequence encoding a chimeric TCR, said chimeric TCR comprising: (i) a first segment encoding either a single-chain TCR (scFv-TCR) made of the variable (V) region and, optionally, of the extracellular constant (C) region, of the TCR, or a two-chain TCR (tcFv-TCR) made of the extracellular variable (V) and constant (C) regions of the TCR, and (ii) a second segment encoding a signal transducing element of an immune cell.
- the scFv-TCR may be the alpha and the beta, or the gamma and the delta, chains of the antigen-specific TCR.
- the said first segment encodes a two-domain (2D) single chain TCR made of the extracellular variable (V) region V ⁇ V ⁇ chains of the TCR linked by a linker.
- the said first segment encodes a three-domain (3D) single chain TCR made of the extracellular variable (V) and constant (C) regions of the TCR.
- a single-chain TCR comprising the V ⁇ V ⁇ C ⁇ or V ⁇ V ⁇ C ⁇ chains of said antigen-specific TCR.
- the first segment is a three-domain (3D) single-chain TCR made of the extracellular variable (V) V ⁇ V ⁇ chains of said antigen-specific TCR and the constant (C) region of the immunoglobulin kappa light chain (Ck).
- the said first segment encodes a two-chain TCR (tcFv-TCR) made of the extracellular variable (V) and constant (C) regions V ⁇ C ⁇ + V ⁇ C ⁇ chains of the TCR.
- the linker that links the V ⁇ V ⁇ chains is selected from standard linkers known in the art such as oligopeptides of 15-20 amino acids that allow flexibility and proper association between the two V domains.
- the signal transducing element may be comprised of the intracellular signalling unit only or of the intracellular signalling unit plus transmembrane domain or of these both and extracellular domain of signalling chains.
- Examples used according to the invention include, but are not limited to, the whole molecules or part of the molecules selcted from TCR/CD3 complex gamma, delta, epsilon, eta or zeta chain, the gamma chain of the Fc receptor, the alpha, beta and/or gamma subunit of the IL-2 receptor, the CD2, CD 16 and CD28 co-receptor chains, the signaling elements of the natural killer (NK) receptor, killing inhibitory receptor (KIR) or killing activating receptor (KAR), or any signaling element derived from an immune cell, and combinations of said signal transducing elements.
- NK natural killer
- KIR killing inhibitory receptor
- KAR killing activating receptor
- Repertoires of T cell receptor fragment genes can be derived from natural sources such as peripheral blood lymphocytes (PBLs), tumor infiltrating T-cells or cloned cytotoxic T cells or cell lines, or can be derived from TCR V-gene segments created in part or completely synthetically.
- PBLs peripheral blood lymphocytes
- the scFv-TCR or tcFv-TCR can be cloned from immune T lymphocytes or from synthetic libraries such as, but not limited to, phage display libraries, viral display libraries or others.
- the variable regions of TCRs can be obtained from human and non-human species T lymphocytes.
- Another object of the present invention is to provide techniques enabling the construction of chimeric TCR chimerized to a signaling element and the introduction of these scFv/ or tcFv/signal transducing molecule into mammalian cells to provide a desired biological action in such cells at a target cell or organ site.
- the transfection of the immune cells with the TCR genes may be performed by any standard method including, but not being limited to, with viral vectors, eukaryotic vectors, and electrical or chemical means such as calcium phosphate transfection, dextrane sulphate transfection, liposomal transfection and electroporation.
- Still another object of the present invention is to provide techniques enabling the construction of proteins which recognize MHC-presented antigens chimerized to a signaling element.
- the immune cell is preferably human.
- Various types of lymphocytes and non-lymphocytic cells may be suitable, for example, resting, activating and memory T lymphocytes, cytotoxic T lymphocytes (CTLs), helper T cells, natural killer (NK) cells, tumor-infiltrating lymphocytes (TIL), non-T lymphocytes, B cells, plasma cells, monocytes, macrophages, eosinophils and dendritic cells, subtypes thereof and any other cell type which can express chimeric receptor chain.
- CTLs cytotoxic T lymphocytes
- NK natural killer
- TIL tumor-infiltrating lymphocytes
- B cells plasma cells
- monocytes macrophages
- eosinophils and dendritic cells subtypes thereof and any other cell type which can express chimeric receptor chain.
- Both antigen-specific and non-specific immune cells are contemplated by the invention.
- the immune cell is an antigen-processing cell and said predefined specificity is targeted antigen uptake and presentation.
- the immune cell is selected from the group consisting of lymphocytes, NK cells, macrophages, monocytes, eosinophils and other cytotoxic cells and said predefined specificity is target cell cytotoxicity.
- the immune cell is a helper T cell and said predefined biological specificity is increased lymphokine or cytokine production.
- the immune cells are B lymphocytes or plasma cells and said predefined specificity is increased immunoglobulin production.
- the immune cells are T cells, B cells, monocytes and macrophages and said predefined biological specificity is increased antigen-presenting functions.
- the immune cell is a target cell immune cell specific for target cell, said immune cell containing an antigen-binding molecule selected from the group consisting of the alpha/beta chains or the gamma/delta chains of the antigen-specific
- T cell receptor chimerized to a signal transducing element selected from the group comprising the TCR/CD3 complex gamma, delta, epsilon, eta or zeta chain, the gamma chain of the Fc receptor, the alpha, beta and/or gamma subunit of the IL-2 receptor, the
- CD2 CD2, CD 16 and CD28 co-stimulatory chains, the signaling elements of the natural killer
- NK killing inhibitory receptor
- KIR killing inhibitory receptor
- KAR killing activating receptor
- the antigen-binding molecule may bind to an antigen including, but not being limited to, viral antigens, synthetic antigens, tumor associated antigens, tumor specific antigens, mucosal antigens, superantigens, differentiation antigens, auto-immune antigens, class I MHC molecules and class II MHC molecules.
- the antigen-binding molecule binds to the melanoma-associated neoplastic protein (MAGE-1) antigen.
- target cell antigen-specific immune and non-immune cells can be created to identify on mammalian cells the MHC-restricted antigenic structure(s) recognized by these relevant chimeric scFv-TCR or tcFv-TCR.
- a technique is provided to identify whether particular antigens against which said TCR are directed are expressed by mammalian cells in vitro or in vivo.
- the present invention further relates to pharmaceutical compositions comprising the immune cells of the invention, which may comprise a pharmaceutically acceptable carrier.
- These pharmaceutical composition may be used for the treatment of cancer, infectious diseases, autoimmune diseases or graft rejection.
- the pharmaceutical composition comprising immune cells containing an antigen-binding molecule that binds MAGE-1, are suitable for the treatment of melanoma.
- the invention further provides a method for treatment of a tumor in a patient comprising transfecting lymphocyte cells of the patient with an antigen-specific
- TCR MHC-restricted chimeric T cell receptor (TCR) gene containing a segment encoding a scFv-TCR or tcFv-TCR which binds to an antigen associated with said tumor and a segment encoding a signal transducing element of an immune cell.
- TCR antigen-specific MHC-restricted chimeric T cell receptor (TCR) gene containing a segment encoding a scFv-TCR or tcFv-TCR which binds to the melanoma-associated neoplastic protein (MAGE-1) antigen and a segment encoding a signal transducing element of an immune cell.
- TCR antigen-specific MHC-restricted chimeric T cell receptor
- Fig. 1A schematically represents a chimeric single chain TCR V ⁇ /V ⁇ - ⁇ [(scFv)-TCRZ ⁇ ] at protein level
- Fig. IB schematically represents some configurations of chimeric TCR constructs: (i) chimeric single chain (ch-sc) TCR V ⁇ V ⁇ C ⁇ genes; (ii) chimeric two chain (ch-tc) TCR ⁇ genes; (Hi) ch-tc TCR ⁇ genes; (iv) full-length TCR ⁇ -chain genes; and (v) full-length TCR ⁇ -chain genes (L, leader; V, variable region; J, joining region; D, diversity region; C, constant region; EC, extracellular region; TM, transmembrane region; Cy, Cytoplasmic region; Li, linker).
- Fig. 2 shows the sequences of the V ⁇ ( A) and V ⁇ @B) chains of the TCR from the MAGE-1 specific CTL clone 82/30, and of the primers used for amplification of the V ⁇ and V ⁇ chains.
- Fig. 3 shows restriction sites used in the construction of the single chain TCR L domain.
- Figs. 4A-4B show the construction of the retroviral vector constructs.
- Figs. 5A-5H illustrate expression of (chimeric-) TCR constructs on primary human T lymphocytes.
- Expression of ( ) chimeric single chain TCR V ⁇ V ⁇ C ⁇ , (ii) chimeric two chain V ⁇ C ⁇ ⁇ /V ⁇ C ⁇ 5 and (Hi) full-length TCR ⁇ ⁇ constructs was determined by flow cytometry after gene transduction of primary human T lymphocytes. Events shown represent viable lymphocytes stained with anti-V ⁇ 12.1 FITC and anti-V ⁇ l PE .
- HLA-A1 restricted, MAGE-1 specific parental CTL clone MZ2-82/30 positive control.
- 5E Human T lymphocytes transduced with V ⁇ C ⁇ - ⁇ and V ⁇ C ⁇ - ⁇ retroviral vectors simultaneously.
- 5F Human T lymphocytes transduced with V ⁇ C ⁇ - ⁇ and V ⁇ C ⁇ - ⁇ retroviral vectors and followed by enrichment by flow sorting using anti-V ⁇ 12.1 FITC and anti-V ⁇ -1 PE mAb.
- 5G Human T lymphocytes transduced with full-length TCR ⁇ and ⁇ retroviral vectors simultaneously.
- Fig. 6 shows that chimeric (scFv)-TCR ⁇ or ⁇ P0S T lymphocytes are able to specifically bind to soluble multimeric HLA-al/MAGE-1 complexes. Complexes with an irrelevant peptide derived from influenza virus nucleoprotein were not bound by the chimeric (scFv)-TCR ⁇ or ⁇ ros T lymphocytes.
- Fig. 7 shows that peptide pulsed target cells are lysed by (chimeric-) TCR transduced human T lymphocytes.
- MAGE-1 peptide-pulsed HLA-Al pos target cells were incubated with the indicated human T lymphocytes and tested in a 6-h 51 Cr release assay.
- Left row and middle row show the data using 51 Cr labeled HLA- Al pos , MAGE-l neg EBV transformed B cell lines 72-2 and APD respectively, pulsed with MAGE-1 or Influenza virus peptides (10 ⁇ g/ml).
- the right row shows the data using 51 Cr labeled HLA-A1 P ° S , MAGE-l neg MEL 2A melanoma cells pulsed with MAGE-1 or influenza virus peptides (10 ⁇ g/ml). Experiments were performed in triplicate, and the SD did not exceed 10%. The per cent specific 51 Cr release is shown at different E:T ratios.
- Figs. 8A-8E shows that native HLA-A1 P0S , MAGE-1 P0S melanoma cells are susceptible to lysis by (chimeric-) TCR transduced T lymphocytes. Cytotolytic capacity of human T lymphocytes was determined in 6-h 51 Cr release assays. Left two rows show results obtained with 51 Cr labeled HLA-Al pos , MAGE-l ros melanoma cells (MZ2-MEL 3.0 and 518A2). The right row shows results obtained with control 51 Cr labeled HLA-A1 NEG , MAGE-1 NEG melanoma cells (MEL 78 — , BLM - - - -) and renal cell carcinoma cells (SKR17 cl4 ). Anti-HLA-ABC (10 ⁇ g/ml, ) or mouse Ig
- Fig. 9 shows that soluble multimeric HLA-A1 /MAGE-1 complexes identify functional CTL expressing retroviral introduced chimeric 3D scFv-TCR and chimeric tc-TCR and full-length TCR ⁇ ⁇ transgenes
- Functional characteristics of human T lymphocytes were determined in flow cytometry and 51 Cr release assays as described in materials and methods.
- HLA-A1 P0S , MAGE-1 P0S melanoma cell was incubated with the human CTL ( ).
- Anti-MHC class I mAb was added (10 ⁇ g/ml, ) to the target and effector cell mixture to demonstrate HLA-Al/MAGE-1 specificity of lysis.
- the 51 Cr labelled HLA-A1 P0S EBV transformed B cell line APD was pulsed with MAGE-1 peptide (10 ⁇ g/ml, , no peptide: ).
- C Flow cytometric analysis of the human T lymphocytes using anti-V ⁇ .l* 1170 and anti-V ⁇ l PE mAbs. DETAILED DESCRD7TION OF THE INVENTION
- the present invention relates to chimeric TCR receptors constructed from the variable regions of the TCR, in particular in the single chain design [(scFv)-TCR], the generation of immune-specific cells such as T lymphocytes, non-T lymphocytes, NK cells, monocytes or macrophages by transfecting these cells with chimeric (single or two gene(s)) T cell receptors.
- immune-specific cells such as T lymphocytes, non-T lymphocytes, NK cells, monocytes or macrophages.
- chimeric TCRs are constructed by chimerizing the sequenced and cloned scFv-TCR or two-chain-Fv-TCR to any signal transducing molecule selected from immune cells, such as, but not limited to, CD2, CD3, CD 16, CD28, ⁇ -chains, ⁇ -chains, KIR, KAR or fragments thereof, etc., and by molecular engineering and subsequently transfecting human or non-human immune cells (specific or non-specific) with genes encoding for scFv chimeric TCR.
- the invention is useful to identify whether target cells express the antigen for which the chimeric TCR is specific.
- the present invention is also useful when it is desirable to use the immune cells expressing the scFv-TCR or tcFv-TCR for immunotherapy of cancer, infectious diseases and autoimmune diseases, including rheumatoid arthritis.
- the present invention provides techniques enabling one with ordinary skill to graft immune cells with chimeric scFv-TCR or tcFv-TCR specificity at will.
- the purpose of transfecting said immune cells is to make the cells specific towards target cells.
- the transfected immune cells of the present invention are triggered as a result of binding of the scFv-TCR or tcFv-TCR to provide a specific biological action such as, but not limited to, targeted antigen uptake and presentation (antigen-processing cells), target cell cytotoxicity (T lymphocytes, NK cells, monocytes, etc.), lymphokine or cytokine production (Helper T cells), Ig production (B lymphocytes and plasma cells), and antigen-presenting functions (T cells, B cells, monocytes, macrophages).
- the present invention creates target cell antigen-specific immune and non-immune cells to identify on mammalian cells the MHC-restricted antigenic structure(s) recognized by the relevant chimeric scFv-TCR or tcFv-TCR.
- a suitable antigen for the purposes outlined here in the present invention is any antigen or target cell membrane expressed molecules against which a T cell response can be mounted in vitro or in vivo or for which such a scFv-TCR or tcFv-TCR can be selected.
- suitable antigens include, but are not limited to, viral antigens, synthetic antigens, tumor-associated antigens (TAA), tumor-specific antigens (TSA), MHC molecules (class I and class II) or autologous antigens.
- TAA tumor-associated antigen
- TSA tumor-specific antigens
- MHC molecules class I and class II
- autologous antigens include, but are not limited to, viral antigens, synthetic antigens, tumor-associated antigens (TAA), tumor-specific antigens (TSA), MHC molecules (class I and class II) or autologous antigens.
- TAA tumor-associated antigens
- TSA tumor-specific antigens
- MHC molecules class I and class II
- autologous antigens autologous antigens.
- chimeric scFv-TCR or tcFv-TCR with specificity for MHC non-restricted antigens such as, but not limited to, mucosal antigens and superantigens
- MHC non-restricted antigens such as, but not limited to, mucosal antigens and superantigens
- chimeric scFv-TCR or tcFv-TCR with specificity for MHC non-restricted antigens such as, but not limited to, mucosal antigens and superantigens
- MHC non-restricted antigens such as, but not limited to, mucosal antigens and superantigens
- cytotoxic T lymphocytes can often be generated against 'non'- or weak lymphocytes, TAA, TSA or viral epitopes, differentiation antigens or other (glyco) proteins.
- antigens which have mutated can act on natural TCR as antagonists to inhibit the CTL response to the wild-type epitope. This leads to T cell anergy and, hence, lack of a host immune response to either tumor TAA, TSA, or virus, leading to e.g., a tumor cell growth or viral persistence.
- Existing technology now allows the creation of peptides and their presentation to T lymphocytes, antigen-presenting cells, resulting in subsequent effective T lymphocyte response.
- the present invention provides (1) selection of scFv- or tcFv-TCR-DNA from natural sources such as PBLs, tumor-infiltrating T cells or cloned cytotoxic T cells or cell lines, or derived from TCR V-gene and, optionally, extracellular C, segments created synthetically, (2) cloning of these scFv- or tcFv-TCR-DNA, and (3) their chimerization to signalling structure and their transfection into immune cells.
- the present invention allows the use of said modified immune cells in adoptive in vivo gene and/or immunotherapy, to combat cancer, virus infections, or autoimmune diseases.
- chimeric scFv-TCR or tcFv-TCR reactive with TCR epitopes on host T cells which cause autoimmunity or graft rejection can be transfected in the host T cells for elimination of the reactive cells following in vivo transfer.
- a wide range of cloned TCR genes chimerized to genes encoding for immune cell signalling molecules with the requisite specificities can be generated by a person having ordinary skill in this art, cloned into the genome of viruses or other vectors and, with existing technology, introduced into host T cells for autologous adoptive gene transfer and/or immunotherapy.
- the chimeric TCR may also be complexed to the immune cells by chemical, physical and/or immunological means by a person having ordinary skill in the art. It is possible that one with ordinary skill may generate MHC negative immune cells to serve as recipient cells for scFv or tcFv chimeric TCR transfection so, that they can be used as universal immune cells for adoptive gene and/or immunotherapy.
- the present invention relates to the functional expression of a cloned scFv-TCR or tcFv-TCR DNA or gene which has been chimerized to signal transducing elements derived from natural sources such as PBLs, tumor-infiltrating T cells or cloned cytotoxic T cells or cell lines into mammalian immune system cells.
- the invention is applicable to situations where it is desirable to have immune cells with a predetermined specificity in order to, e.g., investigate whether mammalian cells express the relative ligand for that chimeric TCR or introduce these chimeric TCR-expressing cells into immune cells of mammals that suffer from cancer, infectious disease or autoimmune diseases.
- the present invention also provides techniques to identify whether particular antigens against which said TCR are directed, are expressed by mammalian cells in vitro or in vivo.
- the invention provides for MHC-restricted antigen-specific immune cells that (following introduction of a scFv- or tcFv- chimeric TCR-gene into these cells) functionally express these receptors on their surface and endows the cells with a predetermined antigen specificity.
- the antigen-binding substance can be selected from TCR, fragments of TCR and antigen-binding peptides other than antibodies.
- MAGE-1 melanoma-associated neoplastic protein
- melanoma-associated neoplastic protein codes for antigens recognized by autologous T lymphocytes on a melanoma tumor. These genes are not expressed in normal tissues except for testis. They are expressed in many tumors of several histological types. Also differentiation antigens coded by genes such as tyrosinase are recognized on human cancer cells by autologous CTL. The identification and characterization of these and other human tumor or viral infected and other tissue cells open the possibility for the systemic approach to specific immunitherapy with the engineered immune cells provided by this invention.
- tumor specific neo-antigens are easily tolerated by the immune system, equivalent of a tissue specific antigen. Therefore, only if tumor specific neo-antigens are effectively processed and presented in vivo or in vitro, will it serve as a dominant target for T lymphocyte immunity. Whether or not a tumor-specific neo-antigen is immunogenic also depends on which tissue type and in what context it is expressed.
- TAA When a TAA is identified, characterized and cloned, it can be introduced in different tissue types so that it becomes immunogenic and specific T lymphocyte immunity can be generated against it (natural sources).
- ScFv- or tcFv-TCR as described in this invention can also be derived from natural sources such as PBLs, tumor infiltrating T-cells or cloned cytotoxic T cells or cell lines or can be derived from TCR V-gene and, optionally, extracellular C-gene, segments created in part or completely synthetically, chimerized to signal transducing elements selected from immune cells and then introduced into immune cells.
- TCR tumor cellular ligands
- TCR with specificities are possible candidates for use within the present invention or any system of the epitope specificity.
- Tumor antigens, viral antigens, MHC-antigens, differentiation antigens, autoimmune antigens and superantigens can be identified using T lymphocytes.
- T lymphocytes are the critical mediators of tumor specific rejection. Consequently, a wide variety of potential tumor antigens and other antigens recognizable by T cells are applicable.
- These chimeric scFv-TCR gene-transduced immune cells can be used for in vivo immunotherapy of cancer, infectious diseases or autoimmune diseases as described, or for the identification of relevant ligands on other mammalian cells.
- the present invention provides an immune cell having predefined biological specificity, wherein said immune cell is grafted with a chimeric T cell receptor.
- the immune cell of the present invention may be made from any human or non-human immune cell.
- Representative examples of immune cells include T lymphocytes, non-T lymphocytes, B cells, monocytes, macrophages, dendritic cells, NK cells plasma cells and Helper T cells.
- the immune cell may be either a specific immune cell and a non-specific immune cell.
- the chimeric T cell receptor is a chimera between a single chain Fv-TCR or a two-chain Fv-TCR and a signal transducing element of an immune cell.
- signal transducing element include CD2, CD3, CD16, CD28, ⁇ -chains, ⁇ -chains, ⁇ -chains, KIR, KAR and fragments thereof.
- the immune cell could be of an antigen processing and presenting cell, immune cell and the predefined biological specificity is targeted antigen uptake and presentation.
- Another embodiment of the present invention provides an immune cell wherein the immune cell is T lymphocyte, B cell macrophage or a monocyte and the predefined biological specificity is target cell cytotoxicity.
- the immune cell can be a helper T cell or other immune cell and the predefined biological specificity is increased lymphokine or cytokine production.
- An alternate form of the immune cell of the present invention is a B lymphocyte or a plasma cell and the predefined biological specificity is increased immunoglobulin production.
- Another alternate form of the immune cell is a mutated T cell, B cell, monocyte or macrophage and said predefined biological specificity is increased antigen presenting functions.
- the immune cell is a NK cell or lymphokine activated cell (LAK), which upon expression of the chimeric TCR can recognize and specifically kill the desired target cell.
- a chimeric receptor based on the killing activating receptor (KAR) or killing inhibitory receptor (KIR) may have very important applications using NK cells.
- the present invention provides a target cell antigen-specific immune cell, said immune cell containing an antigen-binding molecule chimerized to a signal transducing element.
- the antigen-binding molecule may be selected from the group consisting of, but not limited to, T cell receptors, T cell receptor fragments or any protein recognizing and binding to MHC-presented peptides.
- the antigen-binding molecule is a chimeric T cell receptor.
- the chimeric T cell receptor is a 2D or 3D scFv or a tcFv chimeric TCR.
- the antigen-binding molecule binds to a mammalian cell in a MHC restricted fashion or a MHC non-restricted fashion.
- the signal transducing element is selected from the group consisting, but not limited to, CD2, CD3, CD16, CD28, ⁇ -chains, ⁇ -chains, ⁇ -chains, KIR, KAR and fragments thereof.
- the antigen-binding molecule binds to an antigen selected from the group consisting of viral antigens, synthetic antigens, tumor associated antigens, tumor specific antigens, mucosal antigens, superantigens, differentiation antigens, auto-immune antigens, class I major histocompatibility complex molecules, class II major histocompatibility complex molecules and epitopes of antigen-specific T cell receptor or antibodies.
- compositions may be prepared using the novel immune cells of the present invention.
- a person having ordinary skill in this art would readily be able to determine, without undue experimentation, the appropriate dosages and routes of administration of the novel pharmaceutical composition of the present invention.
- the present invention also provides for a pharmaceutical composition comprising the immune cells of the invention.
- the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier as is well known in the art.
- Target cell lines used in this study are: (i) the HLA-A1 P0S , MAGE-1 P0S melanoma cell line MZ2-MEL.3.0, (ii) the HLA-Al pos , MAGE-1 NEG melanoma cell line MZ2-MEL 2.2 (kindly provided by T. Boon and P. Coulie, Brussels, Belgium), (Hi) the HLA-Al pos , MAGE-1 P0S melanoma cell line 518A2 (kindly provided by P.
- the mouse packaging cell line PG13 (ATCC CRL-10686) was used to obtain stable full-length TCR ⁇ ⁇ retrovirus producing cells.
- the CTL clone MZ2-82/30 was used for isolation of RNA coding for the HLA-A1 restricted, MAGE-1 specific TCR (kindly provided by T. Boon and P.
- the mAbs used in this study were: anti-HLA-ABC (clone W6/32, Sera-Lab, Crawley Down, UK), anti-CD4 CY"3 , anti-CD8 FITC/PE (Becton Dickinson Biosciences, San Jose, USA) and the TCR V ⁇ and V ⁇ family specific mAb anti-V ⁇ 12.1 (T Cell Diagnostics, USA) and anti-V ⁇ l (Coulter-Immunotech, Marseille, France).
- Retroviral (chimeric-) TCR gene transduction into primary human T lymphocytes in vitro expansion of transduced T lymphocytes.
- PBL Peripheral Blood Lymphocytes
- anti-CD3 activated lymphocytes were incubated for 72 hrs with an irradiated (25 Gy) monolayer of recombinant retrovirus-producing 293T cells, using culture medium (RPMI 1640 with 25 mM HEPES, 10% human serum, 2mM Glutamine, Penicillin 100 U/ml and streptomycin 100 ⁇ g/ml) supplemented with 4 ⁇ g/ml polybrene (Sigma, St. Louis, U.S.A.), and 360 IU/ml rIL-2 (Proleukin; Chiron, Amsterdam, the Netherlands).
- culture medium RPMI 1640 with 25 mM HEPES, 10% human serum, 2mM Glutamine, Penicillin 100 U/ml and streptomycin 100 ⁇ g/ml
- 4 ⁇ g/ml polybrene Sigma, St. Louis, U.S.A.
- 360 IU/ml rIL-2 Proleukin; Chiron, Amsterdam, the Netherlands.
- Retroviral transduction with full-length TCR ⁇ ⁇ genes was performed with supernatant produced on PG13 packaging cells containing both pBullet TCR ⁇ and TCR ⁇ vectors essentially as described (Van de Griend et al., 1984). Expansion of transduced primary human T lymphocytes was performed in the presence of feeder cells as we described elsewhere (Van de Griend et al. 1984; Pollok et al., 1998).
- the dotplots show viable T lymphoblasts selected by gating on forward (FSC) and sideward (SSC) light scatter signals. Analysis was performed on a FACSCAN instrument (Becton Dickinson Biosciences, San Jose, USA).
- Cytolytic activity of transduced T lymphocytes was measured in 6 hr 51 Cr-release assays as described (Weijtens et al., 1998).
- mAbs were added to the CTL, 15-30 min before addition of the target cells (W6/32: 10 ⁇ g/ml, or irrelevant mlg: 10 ⁇ g/ml).
- Peptide loading of the target cells was performed by addition of 10 ⁇ g/ml MAGE-1 nonapeptide (EADPTGHSY) or irrelevant Influenza peptide derived from Influenza virus A nucleoprotein (CTELKLSDY) to the target cells prior to incubation with effector T lymphocytes.
- EADPTGHSY MAGE-1 nonapeptide
- CELKLSDY irrelevant Influenza peptide derived from Influenza virus A nucleoprotein
- GM-CSF GM-CSF, TNF ⁇ and IFN- ⁇ production.
- GM-CSF and TNF ⁇ production by the gene-transduced T lymphocytes after antigen-specific stimulation 6xl0 4 transduced PBL were cultured for 24 h either in the presence or absence of 2xl0 4 adherent tumor cells in RPMI-1640 medium supplemented with 360 IU/ml rIL-2. At the end of culture, supernatant was harvested and levels of TNF- ⁇ , GM-CSF (Medgenix, Fleurus, Belgium) and IFN- ⁇ (CLB, Amsterdam, the Netherlands) were measured by standard ELISA according to the manufacturers instructions.
- the TCR is a heterodimer which consists of an ⁇ and a ⁇ chain.
- the TCR and ⁇ chains are members of the immunoglobulin gene superfamily and are generated by combined associations of V, J, D and C genes.
- the TCR polypeptides are disulfide linked, highly polymorphic in their N-terminal, variable domains and responsible for antigen recognition.
- Oligonucleotide primers used to synthesize the and p chain cDNA and amplify the V ⁇ , V ⁇ and C ⁇ gene segments (Table 2)
- a fragment of about 350-450 base pairs was isolated from the agarose gel, purified and ligated into pBluescript (Stratagene, USA) as described by Maniatis et al. The ligation mixture was introduced into bacteria which were selected and expanded. DNA was isolated from these selected bacterial colonies and analyzed by restriction enzyme digestion to confirm the presence of the amplified TCR ⁇ fragment.
- TCR V ⁇ chain For cloning of the TCR ⁇ chain, a different approach was followed. First, to determine to which family the TCR V ⁇ chain belongs, a family typing PCR (Thor Straten, P. et al. 1994) was performed. Twenty-one different TCR variable ⁇ chains have been described. In a family typing PCR, the template cDNA was divided into separate samples that are each individually amplified with a family specific 5' primer and a constant primer. Multiple PCR reactions had yielded amplified fragments. In order to determine which fragment corresponded to the TCR V ⁇ fragment, a Southern blot was performed (Maniatis et al.) with a 32 P-labeled C ⁇ probe.
- a cloning vector was designed that allows easy construction of single chain molecules.
- the vector was made by replacement of the multiple cloning sites in pBluescript (Stratagene) by a specially designed poly linker (Table 3).
- primers were designed that allowed cloning of these fragments in front of the flexible linker sequence or after the linker sequences (Fig. 2).
- TCR V ⁇ and TCR V ⁇ fragments For amplification of the TCR V ⁇ and TCR V ⁇ fragments, two separate PCR reactions were performed to generate fragments that include the signal sequence of the V region and fragments that start practically at the beginning of the mature protein.
- the DNA fragments were digested with restriction enzymes that allow cloning next to the flexible linker. Positive bacterial colonies were grown for DNA purification and DNA was subjected to DNA sequencing. DNA clones with the correct sequence were used to construct the chimeric single chain TCR constructs.
- the clones containing either the TCR V ⁇ or the TCR V ⁇ fragments in front of the flexible linker sequence were then ligated to the TCR V ⁇ and TCR V ⁇ fragments which lack the signal sequence.
- three different single chain TCRs were constructed (V ⁇ -212 linker-V ⁇ , V ⁇ -212 linker-V ⁇ and V ⁇ -(Gly 4 Ser) 3 , linker-V ⁇ ), see Figure 3.
- RNA isolated from CTL clone 82/30 was amplified using V ⁇ -ATG and C ⁇ -cys primers and V ⁇ and C ⁇ -cys primers respectively. (Table 5).
- V ⁇ C ⁇ and V ⁇ C ⁇ genes ( ⁇ ⁇ ) .
- V ⁇ C ⁇ and V ⁇ C ⁇ were each ligated 5' to the ⁇ gene in pBluescript. Correct sequences of chimeric
- V ⁇ C ⁇ and V ⁇ C ⁇ constructs were then cloned into the pSTITCH retroviral vector.
- the chimeric single chain V ⁇ -212 linker-V ⁇ _ ⁇ construct was ligated into the SFG retroviral vector ( Figure 4) by standard cloning techniques.
- Figure 4 For the generation of virus producing amphotropic packaging cell lines the
- SFG-V ⁇ -212-V ⁇ - ⁇ retroviral vector was electroplated into the amphotropic packaging cell line PA317, using the BTX electro cell manipulator 600 (settings: 760 uF, 250 V, 129 Q)- PA317 cells expressing the V ⁇ -212-V ⁇ - ⁇ chain were selected by a monoclonal antibody directed against the V ⁇ chain (Diversi-T 0 " V ⁇ 12, T cell Diagnostics, Cambridge, USA) bound to goat anti-mouse coated magnetic particles.
- the packaging cells containing the SFG-V ⁇ -212-V ⁇ - ⁇ construct were used to transduce anti-CD3 activated human PBL.
- the retroviral vector pBullet_ was constructed. After removal of two Nco I sites (positions 316 and 3952) and the Xho I site (position 3834), in the retroviral vector pSTITCH (Weijtens, M.E.M., et al. 1998) a multiple restriction site sequence was introduced. The resulting vector was named pBullet.
- an expression cassette sequence was introduced containing the signal sequence from the G250 mAb Variable heavy chain, two cloning sites for introduction of the three domain single chain TCR and a signal transducing element.
- Two signal transducing elements have been introduced: one containing a short constant Ig kappa chain sequence Ck, extracellular domain of ⁇ , the CD4 transmembrane domain and the intracellular domain of the ⁇ chain.
- the other signal-transducing element comprises the complete ⁇ , chain, starting at the Bam H I site present in r.
- TCR/ ⁇ or ⁇ viruses PG13 packaging cells were cocultivated for two days with irradiated 293T cells (25 Gray), transfected with a: the retroviral vector pBullet 3D/CkCD4Tm ⁇ or pBullet 3D/ ⁇ b: the amphotropic envelope construct pEUT 456 and c: the GAG-POL construct pHIT 60.
- the efficiency of retrovirus production by PG13 packaging cell lines PG13-3DCkCD4T ⁇ _ ⁇ and PG13-3D ⁇ was determined by applying serial dilutions of viral supernatant to 293T cells, which were analyzed two days later for the percentage of V ⁇ 12.1 pos , V ⁇ l pos cells.
- Stable high producer PG13 packaging cells were used to produce viral supernatant used to transduce anti-CD3 activated human PBL.
- PBMC peripheral blood mononuclear cells
- mAb anti-CD3 monoclonal antibody
- IL-2 recombinant interleukin-2
- Retroviral transduction of chimeric TCR ⁇ ⁇ / ⁇ gene constructs and chimeric (scFv)-TCR ⁇ / ⁇ gene constructs was performed by incubating human T lymphocytes with 293T packaging cells that were transiently transfected with: (0 two retroviral vectors each comprising chimeric TCR ⁇ ⁇ gene constructs; (ii) a vector containing the retroviral Gibon Ape Leukemia virus envelope and (iii) a vector containing the viral GAG and POL genes.
- the full-length TCR ⁇ and ⁇ genes were introduced into human T lymphocytes derived from a different donor by incubation with supernatant obtained from PG13 packaging cells that contain both full-length TCR ⁇ and ⁇ genes.
- Flow cytometric analysis of gene-transduced T lymphocytes demonstrated expression of the chimeric-TCR ⁇ / ⁇ an ⁇ chimeric 3D (scFv)-TCR ⁇ or ⁇ transgenes in 25 to 40% of primary activated, human T lymphocytes as evidenced by the strictly coordinated reactivity with anti-TCR V ⁇ -12.1 and anti-V ⁇ -1 family typing mAbs respectively
- Fig. 5 shows the expression of (i) chimeric single chain TCR V ⁇ V ⁇ C ⁇ , (ii) chimeric two chain V ⁇ C ⁇ ⁇ /V ⁇ C ⁇ ⁇ and (iii) full-length TCR ⁇ ⁇ constructs which was determined by flow cytometry after gene transduction of primary human T lymphocytes.
- H Human T lymphocytes transduced with full-length TCR ⁇ and ⁇ retroviral vectors, followed by V ⁇ 12.1 immunomagnetic selection and a second enrichment by flow sorting using soluble multimeric HLA-Al/MAGE-l/Strep PE complexes. FACS analysis using anti-V ⁇ 12.1 and anti V ⁇ l show identical fluorescence signals as the 3D scFv TCR V ⁇ V ⁇ C ⁇ .
- EXAMPLE 6 (Chimeric) (scFv)-TCR ⁇ or r * °° s T lymphocytes bind soluble multimeric HLA-Al/MAGE-1 complexes.
- HLA-A1 binding MAGE-1 peptide EADPTGHSY and an irrelevant HLA-A1 binding peptide derived from Influenza virus A nucleoprotein (CTELKLSDY) were used to construct soluble peptide-MHC complexes for the identification of antigen specific TCR on gene transduced T lymphocytes.
- Tetrameric (or multimeric) complexes comprising soluble MHC class I molecules with antigenic peptides and PE conjugated streptavidin are reagents that allow the identification of MHC restricted, antigen specific T lymphocytes.
- Binding of tetrameric complexes has been shown to correlate with recognition of viral antigens presented by virally infected cells or tumor associated antigens presented on tumor cells by cytotoxic T cells (Cole et al., 1995). Tetramer binding T cells were shown to recognize and kill virally infected cells or tumor cells.
- HLA-A1 heavy chain was cloned by the following protocol: The gene coding for the HLA-A101 gene was amplified by PCR using the primers
- the restriction sites Ncol and Notl used for cloning are underlined.
- the forward primers encode the peptide HHILDAQKMVWNHR recognized by the BirA enzyme used for in vivo biotinylation (see below).
- the PCR products were ethanol-precipitated, digested with Ncol and Notl enzymes, gel-purified and ligated into the plasmid pET21d (Novagen, Madison,USA) digested with the same enzymes.
- the plasmids were transformed into DH5 ⁇ and clones containing an insert were sequenced. Clones with the correct sequence were then transformed into BL21DE3 for protein production, together with a compatible plasmid containing the Bir A gene under the control of the tac promoter (pBirCm, AvidityTM, denvers, USA).
- the plasmid pHN ⁇ 2m was used to produce the ⁇ 2m.
- HLA-A1 protein and ⁇ 2m protein were purified by inclusion body purification:
- HLA-A1 proteins The inclusion body purification of HLA-A1 proteins was done by a 10-ml overnight bacterial culture was diluted in one liter of 2xTY containing 100 ⁇ g/ml ampicillin and 15 ⁇ g/ml chloramphenicol and incubated at 37°C with agitation. At OD600 of 0.5, ImM IPTG and 50 ⁇ M biotin was added and the bacterial culture was incubated at 37°C for 3-4 h. The bacterial culture was centrifuged and the pellet was resuspended in 20 ml of lysis buffer (25% sucrose, 1 mM EDTA, 50 mM Tris-Hcl pH 8).
- 200 ⁇ l of 100 mM PMSF in isopropanol and 1 ml of 10 ⁇ g/ml lysozyme were added and the bacteria were incubated 30 min on ice.
- 200 ⁇ l of IM MgC12, 20 ⁇ l of IM MnC12 and 20 ⁇ l of 10 ⁇ g/ml DNAsel were added and the mix was incubated again 20 min on ice.
- the bacterial pellet was resuspended in 20 ml of detergent buffer (0.2 M Nacl, 1% DOC, 1% Nonindet P40, 2 mM EDTA, 20 mM Tris 7.5). 40 ⁇ l of IM DTT and 200 ⁇ l of 100 mM PMSF were added.
- HLA-A1 /peptide complexes were reconstituted by dilution:
- the inclusion bodies were thawed, centrifuged for 10 min at 10 000 rpm, and the protein pellet was dissolved in the same volume of urea buffer (50% urea, 50 mM NaCl, 20 mM Tris 7.5, 5 mM reduced glutathion). After a 10 min centrifugation at 10,000 rpm, the supernatant was used for refolding.
- the complex formation was initiated by dilution of the two denatured subunits and peptide into 200 ml of refolding buffer (400 mM Arginine/Hcl, 2 mM EDTA, 5 mM reduced glutathion, 0.5 mM oxidized glutation, 100 mM Tris-Hcl pH 7.5).
- the amount of heavy chain, ⁇ 2m and peptide were respectively 6 mg, 5 mg and 2 mg.
- the solution was incubated without agitation for 36h at 4°C and then concentrated with Centriprep-10 from 200 ml to 700 ⁇ l.
- the concentrated protein was subjected to gel filtration on a Superdex 200 column (Pharmacia, Uppsala, Sweden) and the peak corresponded to 48 kDa was collected.
- Multimeric HLA-Al/peptide/streptavidin PE complexes used for staining of transduced lymphocytes were made by mixing equal volumes of streptavidin PE (5 ⁇ g/ml, Becton Dickinson Biosciences, San Jose, USA) and soluble HLA-A1 /peptide (120 ⁇ g/ml), followed by 30 min incubation on ice. Chimeric (scFv)-TCR ⁇ / ⁇ , were incubated for 30 min with 1:10 dilution of a fresh preparation of multimeric
- HLA-Al/MAGE-l/Streptavidin PE complexes or HLA-Al/Influenza/Streptavidin PE complexes at 4°C
- MAGE-l/HLA-Al/streptavidin PE multimers specifically stained the genetically introduced chimeric two chain- ⁇ ⁇ / ⁇ ⁇ chimeric scFv TCR/ ⁇ and full-length ⁇ ⁇ TCRs expressed on human T lymphocytes, but not control multimeric HLA-Alcomplexes presenting the Influenza peptide. Neither did control T lymphocytes, that were transduced with the enhanced green fluoresence protein (EGFP) transgene, recognize and bind soluble multimeric HLA-Al/MAGE-1 complexes. FACS analysis using multimeric HLA-Al/MAGE-1 complexes show identical fluorescence signals as the 3D scFv TCR V ⁇ V ⁇ C ⁇ .
- EGFP enhanced green fluoresence protein
- MAGE-1 peptide loaded target cells specifically trigger lysis by (i) chimeric 3D scFv-, (ii) chimeric tc- and (iii) full length-TCR POS T lymphocytes.
- HOLA-AlTM 8 , MAGE-lTM 8 melanoma cells specifically trigger lysis by chimeric (scFv)- TCR POS ⁇ lym p hocyt es
- HLA-A1 P0S /MAGE-1 P0S melanoma cell lines and control HLA-A1 NEG cell lines were incubated with the chimeric 3D (scFv)-TCR P0S , tc-TCR P0S and full-length TCR P0S T lymphocytes to determine the HLA-A1 restricted, MAGE-1 specificity of the transduced T lymphocytes.
- Fig.8 sorted chimeric 3D scFv-TCR p0S , tc-TCR P0S and sorted-full-length TCR P0S T lymphocytes specifically lysed the HLA-A1 P0S , MAGE-1 P0S melanoma cells MZ2-MEL 3.0 and 518A2, but not the HLA-A1 NEG control cell lines (MEL 78, BLM and SKRC17-4) in a 6 hour incubation period. Further proof of MAGE-1 specificity of transduced T lymphocytes came from the addition of anti-MHC class I mAb, which resulted in significant lower tumor cell lysis, whereas irrelevant mAb did not inhibit cytolytic activity (Fig 8).
- HLA-A1 restricted, MAGE-1 specificity of the chimeric 3D scFv-TCR P0S , tc-TCR pos and full length TCR P0S T lymphocytes was analyzed by incubating these cells with MAGE-1 peptide pulsed HLA-A1 P0S , MAGE-1 NEG Melanoma cells MZ2-MEL 2.2 and HLA-A1 P0S , MAGE-1 P0S melanoma cells MZ2-MEL 3.0. After 24 hour incubation supernatant was harvested and analyzed for the presence of TNF ⁇ , GM-CSF and IFN ⁇ .
- Table 6 shows the results of the incubation of the CTL with HLA-A1 P0S , MAGE-1 P0S melanoma cells and MAGE-1 peptide pulsed melanoma cells significant amounts of these lymphokines were produced.
- Soluble multimeric HLA-Al/MAGE-1 complexes identify functional (i) chimeric 3D scFv-TCR, (ii) chimeric tc-TCR and (Hi) full length TCR expressing T lymphocytes.
- Soluble mulimeric HLA-Al/MAGE-1/streptavidin complexes could be used to identify and select peptide specific cells from bulk cultured gene transduced T lymphocytes. Therefore, chimeric 3D scFv-TCR, chimeric tc-TCR and full-length TCR ⁇ ⁇ gene transduced T lymphocytes were sorted with soluble multimeric HLA-Al/MAGE-l/streptavidin PE complexes. Positive and negative fractions obtained by sorting were expanded and analyzed for HLA-A1 restricted, MAGE-1 specificity. As shown in figure 9, CD8 P0S chimeric 3D scFv-TCR, chimeric tc-TCR and full-length
- both the negatively and positively sorted Full-length TCR ⁇ ⁇ gene transduced T lymphocytes express the introduced TCR ⁇ ⁇ as determined by flow cytometry using family typing mAbs anti-V ⁇ 12.1 Fr ⁇ c and anti-V ⁇ l PE .
- Tyrosinase Melanoma Melanocytes Melanosomal protein
- V ⁇ -ATG 5' GCG AAT TCT ACG TAC CAT GAA CAT GCT GAC TGC CAG C3 ⁇ V ⁇ -3 5' CGT CTA GAG GAC AGA AGG TAA CTC AAG CGC AG 3' V ⁇ -ATG: 5' CCG AAT TCT ACG TAC CAT GGG CTT CAG GCT GCT CTG 3> V ⁇ -3 5' GCG GAT CCG AGC ACT GTC AGC CGG GTG CC 3'
- V ⁇ 5' primer for reamplification 5'-GCG-AAT-TCT-ACG-TAC-CAT-
- TCR V ⁇ 3 5.-TTG-TTC-TGC-GGC-CGC-GAG-CAC-TGT-CAG-GGT- GCC-TG-3' Table 6 : Chimeric TCR expressing T cells undergo specific stimulation to produce cytokines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Immune cells having predefined specificity are obtained by either complexing the cells with an antigen-specific MHC-restricted chimeric T cell receptor (TCR) or a fragment thereof, or transfecting said cells with an antigen-specific MHC-restricted chimeric TCR gene. The chimeric TCR comprises: (i) a first segment comprising either (a) a single-chain TCR (scFv-TCR) made of the variable (V) region and, optionally, of either the extracellular constant (C) region of an antigen-specific TCR, or of the constant region of the immunoglobulin kappa light chain (Ck); or (b) a two-chain TCR (tcFv-TCR) made of the extracellular variable (V) and constant (C) regions of an antigen-specific TCR; and (ii) a second segment comprising a signal transducing element of an immune cell. The immune cells can be used for example for the treatment of cancer, infectious diseases, autoimmune diseases or graft rejection.
Description
IMMUNE CELLS HAVING PREDEFINED BIOLOGICAL SPECI FICITY , COMPRISING CHIMERIC T CELL RECEPTOR
BACKGROUND OF THE INVENTION Field of the Invention
The present invention relates generally to the fields of immunology and molecular cell biology. More specifically, the present invention relates to immune cells complexed with a chimeric T cell receptor (TCR) or a fragment thereof, or transfected with a chimeric TCR gene.
Description of the Related Art
The immune response is a complex defense system able to recognize and kill invading organisms, e.g., bacteria, viruses, fungi, allogeneic tissue and some types of tumor cells. The characteristic aspects of the immune system are the specific recognition of antigens, the ability to discriminate between self and non-self antigens and a "memory" which enables a quick, specific reaction to previously encountered antigens. The immune system in mammals reacts to antigens via both humoral and cell-mediated immune responses.
The major pathway of the immune defense begins with the trapping of the antigen by accessory cells such as dendritic cells or macrophages with subsequent concentration in lymphoid organs. Upon specific recognition of the processed antigen, mature T helper cells can be triggered to become activated T helper cells. These activated T helper cells regulate both the humoral immune response by inducing the differentiation of B cells to antibody-producing plasma cells and control of cell-mediated immune response by activation of cytotoxic T lymphocytic (CTL) cells and natural killer (NK) cells.
T lymphocytes recognize antigen in the context of self Major Histocompatibility Complex (MHC) molecules by means of the T cell receptor (TCR). The TCR expressed on the surface of T cells is a disulfide-linked heterodimer non-covalently associated with an invariant structure, the CD3 complex. CD3 is assumed to be responsible for intracellular signalling following occupancy of the TCR by ligand. Most T cells carry TCRs consisting of a and β glycoproteins (α and β chains of the TCR), while some T cells carry TCRs having γ and δ glycoproteins (γ and δ chains).
Like the immunoglobulin (Ig) genes, the TCR genes are composed of variable
segments which rearrange during T cell development. TCR, like Ig polypeptides, consist of amino terminal variable (N) and carboxyl terminal constant (C) regions. The variable region V is responsible for the specific recognition of antigen whereas the constant C region functions in membrane anchoring and in transmitting of the signal that the receptor is occupied, from the outside to the inside of the cell. The variable regions of the Ig heavy chain and the TCR β chain are encoded by three gene segments, the variable (V), diversity (D) and joining (J) segments. The Ig light chain and the TCR α chain contain variable regions encoded by N and J segments.
The T cell receptor for antigen-CD3 complex (TCR/CD3) recognizes antigenic peptides that are presented to it by the MHC proteins. Complexes of MHC and peptide are expressed on the surface of antigen presenting cells and other T cell targets. Stimulation of the TCR/CD3 complex results in activation of the T cell and a consequent antigen-specific immune response. The TCR/CD3 complex plays a central role in the effector function and regulation of the immune system. Two forms of T cell receptor for antigen are expressed on the surface of T cells.
These contain either α/β heterodimers or γ/ δ heterodimers. Accordingly, each of these chains is made of the V and C regions of the TCR, namely NαCα , V« C„ , V C , and
NgCg .T cells are capable of rearranging the genes that encode the α, β, γ and 5 chains of the T cell receptor. T cell receptor gene rearrangements are analogous to those that produce functional immunoglobulins in B cells and the presence of multiple variable and joining regions in the genome allows the generation of T cell receptors with a diverse range of binding specificities. Each α/β or γ/ heterodimer is expressed on the surface of the T cell in association with four invariant peptides. These are the γ, δ and ε subunits of the CD3 complex and the zeta chain. The CD3 γ, and ε polypeptides are encoded by three members of the immunoglobulin supergene family and are found in a cluster on human chromosome 11 or murine chromosome 9. The zeta chain gene is found separately from other TCR and CD3 genes on chromosome 1 in both the mouse and human. The
CD3 chains and the zeta subunit do not show variability, and are not involved directly in antigen recognition. All the components of the T cell receptor are membrane proteins and consist of a leader sequence, externally-disposed Ν-terminal extracellular domains, a single membrane-spanning domain, and cytoplasmic tails. The α, β, γ and δ antigen-binding
polypeptides are glycoproteins. The zeta chain hasa relatively short ectodomain of only nine amino acids and a long cytoplasmic tail of approximately 110 amino acids. Most T cell receptor α/β heterodimers are covalently linked through disulphide bonds, but many γ/δ receptors associate with one another non-covalently. The zeta chain quantitatively forms either disulphide-linked ς-η heterodimers or zeta-zeta homodimers.
Another example of a type of receptor on cells of the immune system is the Fc receptor. The interaction of antibody-antigen complexes with cells of the immune system results in a wide array of responses, ranging from effector functions such as antibody-dependent cytotoxicity, mast cell degranulation, and phagocytosis to immunomodulatory signals such as regulating lymphocyte proliferation, phagocytosis and target cell lysis. All these interactions are initiated through the binding of the Fc domain of antibodies or immune complexes to specialized cell surface receptors on hematopoietic cells. It is now well established that the diversity of cellular responses triggered by antibodies and immune complexes results from the structural heterogeneity of Fc receptors (FcRs).
FcRs are defined by their specificity for immunoglobulin isotypes. Fc receptors for IgG are referred to as FcγR, for IgE as FcεR, for IgA as FcαR, etc. Structurally distinct receptors are distinguished by a Roman numeral, based on historical precedent. We now recognize three groups of FcγRs, designated FcγRI, FcγRII and FcγRiπ. Two groups of FcεR have been defined; these are referred to as FcεRI and FcgRQ. Structurally related although distinct genes within a group are denoted by A, B, C. Finally, the protein subunit is given a Greek letter, such as FcγRIIIAα, FcγRIIIAγ. All the CD3 chains (γ, δ, ε, ς and η) and the FcR-γ chain contain Immunoreceptor Tyrosine Activation Motifs (ITAMs) which undergo phosphorilation and is responsible for the signal transduction of the cells.
Considerable progress has been made in defining the heterogeneity for IgG and IgE Fc receptors (FcγR, FcεR) through their molecular cloning. Those studies make it apparent that Fc receptors share structurally related ligand binding domains, but differ in their transmembrane and intracellular domains which presumably mediate intracellular signalling. Thus, specific FcγRs on different cells mediate different cellular responses upon interaction with an immune complex. The structural analysis of the FcγRs and FcgRI has also revealed at least one common subunit among some of these receptors. This common subunit is the γ subunit, which is similar to the or η chain of the
TCR/CD3, and is involved in the signal ttansduction of the FcγRIII and FcεRI throug its ITAM motif.
The low affinity receptor for IgG (FcγRIHA), is composed of the ligand binding
CD16α (FcγRIHAα) polypeptide associated with the γ chain (FcγRIOAγ). The CD16 polypeptide appears as membrane anchored form in polymorphonuclear cells and as transmembrane form (CD16TM) in NK cells. The FoyRDIA serves as a triggering molecule for NK cells.
Another type of immune cell receptor is the IL-2 receptor. This receptor is composed of three chains, the α chain (p55), the β chain (pi 5) and the γ chain. When stimulated by IL-2, lymphocytes undergo proliferation and activation.
Antigen-specific effector lymphocytes, such as tumor specific T cells (Tc), are very rare, individual-specific, limited in their recognition spectrum and difficult to obtain against most malignancies. Antibodies, on the other hand, are readily obtainable, more easily derived, have wider spectrum and are not individual-specific. The major problem of applying specific antibodies for cancer immunotherapy lies in the inability of sufficient amounts of monoclonal antibodies (mAb) to reach large areas within solid tumors. In practice, many clinical attempts to recruit the humoral or cellular arms of the immune system for passive anti-tumor immunotherapy have not fulfilled expectations. While it has been possible to obtain anti-tumor antibodies, their therapeutic use has been limited so far to blood-borne tumors primarily because solid tumors are inaccessible to sufficient amounts of antibodies. The use of effector lymphocytes in adoptive immunotherapy, although effective in selected solid tumors, suffers on the other hand, from a lack of specificity (such as in the case of lymphokine-activated killer cells (LAK cells) which are mainly NK cells) or from the difficulty in recruiting tumor-infiltrating lymphocytes (TILs) and expanding such specific T cells for most malignancies. Yet, the observations that TBLs can be obtained in melanoma and renal cell carcinoma tumors, that they can be effective in selected patients and that foreign genes can function in these cells demonstrate the therapeutic potential embodied in these cells.
PCT WO/94/29438 describes a method for transducing mammalian target cells with foreign genes, e.g. a gene encoding a chimeric T cell receptor, comprising transient cotransfection of a first population of mammalian cells that can produce virus with a retroviral packaging plasmid and a retroviral vector encoding a foreign gene, and cocultivation of said first population of mammalian cells producing replication-defective
recombinant retroviral vectors carrying said foreign gene with a second population of mammalian target cells to transduce said second population of target cells with said foreign gene. The TCR contains a non-MHC restricted extracellular surface membrane protein domain binding specifically to at least one ligand. The prior art is deficient in the lack of effective means of treating cancer and effectively treating a wide variety of immunologically based disease conditions, particularly autoimmune diseases and graft rejection.
SUMMARY OF THE INVENTION It is an object of the present invention is to endow immune cells with a predefined specificity by grafting immune cells with chimeric TCR specificity.
The present invention relates to an immune cell having predefined specificity, wherein said immune cell is either complexed with an antigen-specific MHC-restricted chimeric T cell receptor (TCR) or a fragment thereof, or is transfected with an antigen-specific MHC-restricted chimeric TCR gene.
In one embodiment, the immune cell is complexed with the TCR or TCR fragment by chemical conjugation. The TCR or TCR fragment may also be bridged to the immune cell by a macromolecule linker such as, but not being limited to, avidin, streptavidin or poly ly sine, or by a bispecific antibody that binds both to the TCR or TCR fragment and to the immune cell.
In another embodiment, the immune cell is transfected with a chimeric TCR gene or a DNA sequence encoding a chimeric TCR, said chimeric TCR comprising: (i) a first segment encoding either a single-chain TCR (scFv-TCR) made of the variable (V) region and, optionally, of the extracellular constant (C) region, of the TCR, or a two-chain TCR (tcFv-TCR) made of the extracellular variable (V) and constant (C) regions of the TCR, and (ii) a second segment encoding a signal transducing element of an immune cell. The scFv-TCR may be the alpha and the beta, or the gamma and the delta, chains of the antigen-specific TCR.
In one embodiment of the invention, the said first segment encodes a two-domain (2D) single chain TCR made of the extracellular variable (V) region VαVβchains of the TCR linked by a linker. In another embodiment, the said first segment encodes a three-domain (3D) single chain TCR made of the extracellular variable (V) and constant (C) regions of the TCR. Such as a single-chain TCR comprising the VαVβCβ or VαVβCα chains of said
antigen-specific TCR. In a further embodiment, the first segment is a three-domain (3D) single-chain TCR made of the extracellular variable (V) VαVβ chains of said antigen-specific TCR and the constant (C) region of the immunoglobulin kappa light chain (Ck). In a further embodiment, the said first segment encodes a two-chain TCR (tcFv-TCR) made of the extracellular variable (V) and constant (C) regions Vα Cα+ VβCβ chains of the TCR.
The linker that links the VαVβ chains is selected from standard linkers known in the art such as oligopeptides of 15-20 amino acids that allow flexibility and proper association between the two V domains.
The signal transducing element may be comprised of the intracellular signalling unit only or of the intracellular signalling unit plus transmembrane domain or of these both and extracellular domain of signalling chains. Examples used according to the invention include, but are not limited to, the whole molecules or part of the molecules selcted from TCR/CD3 complex gamma, delta, epsilon, eta or zeta chain, the gamma chain of the Fc receptor, the alpha, beta and/or gamma subunit of the IL-2 receptor, the CD2, CD 16 and CD28 co-receptor chains, the signaling elements of the natural killer (NK) receptor, killing inhibitory receptor (KIR) or killing activating receptor (KAR), or any signaling element derived from an immune cell, and combinations of said signal transducing elements.
Repertoires of T cell receptor fragment genes can be derived from natural sources such as peripheral blood lymphocytes (PBLs), tumor infiltrating T-cells or cloned cytotoxic T cells or cell lines, or can be derived from TCR V-gene segments created in part or completely synthetically. The scFv-TCR or tcFv-TCR can be cloned from immune T lymphocytes or from synthetic libraries such as, but not limited to, phage display libraries, viral display libraries or others. The variable regions of TCRs can be obtained from human and non-human species T lymphocytes.
Another object of the present invention is to provide techniques enabling the construction of chimeric TCR chimerized to a signaling element and the introduction of these scFv/ or tcFv/signal transducing molecule into mammalian cells to provide a desired biological action in such cells at a target cell or organ site. The transfection of the immune cells with the TCR genes may be performed by any standard method including, but not being limited to, with viral vectors, eukaryotic vectors, and electrical or
chemical means such as calcium phosphate transfection, dextrane sulphate transfection, liposomal transfection and electroporation.
Still another object of the present invention is to provide techniques enabling the construction of proteins which recognize MHC-presented antigens chimerized to a signaling element.
The immune cell is preferably human. Various types of lymphocytes and non-lymphocytic cells may be suitable, for example, resting, activating and memory T lymphocytes, cytotoxic T lymphocytes (CTLs), helper T cells, natural killer (NK) cells, tumor-infiltrating lymphocytes (TIL), non-T lymphocytes, B cells, plasma cells, monocytes, macrophages, eosinophils and dendritic cells, subtypes thereof and any other cell type which can express chimeric receptor chain. Both antigen-specific and non-specific immune cells are contemplated by the invention.
In one embodiment, the immune cell is an antigen-processing cell and said predefined specificity is targeted antigen uptake and presentation. In another embodiment, the immune cell is selected from the group consisting of lymphocytes, NK cells, macrophages, monocytes, eosinophils and other cytotoxic cells and said predefined specificity is target cell cytotoxicity.
In a further embodiment, the immune cell is a helper T cell and said predefined biological specificity is increased lymphokine or cytokine production. In still another embodiment, the immune cells are B lymphocytes or plasma cells and said predefined specificity is increased immunoglobulin production.
In yet a further embodiment, the immune cells are T cells, B cells, monocytes and macrophages and said predefined biological specificity is increased antigen-presenting functions. In another further embodiment, the immune cell is a target cell immune cell specific for target cell, said immune cell containing an antigen-binding molecule selected from the group consisting of the alpha/beta chains or the gamma/delta chains of the antigen-specific
T cell receptor, chimerized to a signal transducing element selected from the group comprising the TCR/CD3 complex gamma, delta, epsilon, eta or zeta chain, the gamma chain of the Fc receptor, the alpha, beta and/or gamma subunit of the IL-2 receptor, the
CD2, CD 16 and CD28 co-stimulatory chains, the signaling elements of the natural killer
(NK) receptor, killing inhibitory receptor (KIR) or killing activating receptor (KAR), or any signaling element derived from an immune cell, and combinations of said signal
transducing elements.
The antigen-binding molecule may bind to an antigen including, but not being limited to, viral antigens, synthetic antigens, tumor associated antigens, tumor specific antigens, mucosal antigens, superantigens, differentiation antigens, auto-immune antigens, class I MHC molecules and class II MHC molecules. In one embodiment, the antigen-binding molecule binds to the melanoma-associated neoplastic protein (MAGE-1) antigen.
According to the invention, target cell antigen-specific immune and non-immune cells can be created to identify on mammalian cells the MHC-restricted antigenic structure(s) recognized by these relevant chimeric scFv-TCR or tcFv-TCR. In addition, a technique is provided to identify whether particular antigens against which said TCR are directed are expressed by mammalian cells in vitro or in vivo.
The present invention further relates to pharmaceutical compositions comprising the immune cells of the invention, which may comprise a pharmaceutically acceptable carrier. These pharmaceutical composition may be used for the treatment of cancer, infectious diseases, autoimmune diseases or graft rejection. The pharmaceutical composition comprising immune cells containing an antigen-binding molecule that binds MAGE-1, are suitable for the treatment of melanoma.
The invention further provides a method for treatment of a tumor in a patient comprising transfecting lymphocyte cells of the patient with an antigen-specific
MHC-restricted chimeric T cell receptor (TCR) gene containing a segment encoding a scFv-TCR or tcFv-TCR which binds to an antigen associated with said tumor and a segment encoding a signal transducing element of an immune cell.
Still further provided is a method of treatment of melanoma in a patient comprising transfecting lymphocyte cells of the patient with an antigen-specific MHC-restricted chimeric T cell receptor (TCR) gene containing a segment encoding a scFv-TCR or tcFv-TCR which binds to the melanoma-associated neoplastic protein (MAGE-1) antigen and a segment encoding a signal transducing element of an immune cell.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1A schematically represents a chimeric single chain TCR Vα/Vβ-γ [(scFv)-TCRZγ] at protein level; Fig. IB schematically represents some configurations of chimeric TCR constructs: (i) chimeric single chain (ch-sc) TCR VαVβCβζ genes; (ii)
chimeric two chain (ch-tc) TCR ς genes; (Hi) ch-tc TCR βζ genes; (iv) full-length TCR α-chain genes; and (v) full-length TCR β-chain genes (L, leader; V, variable region; J, joining region; D, diversity region; C, constant region; EC, extracellular region; TM, transmembrane region; Cy, Cytoplasmic region; Li, linker). Fig. 2 shows the sequences of the Vα ( A) and Vβ @B) chains of the TCR from the MAGE-1 specific CTL clone 82/30, and of the primers used for amplification of the Vα and Vβ chains.
Fig. 3 shows restriction sites used in the construction of the single chain TCR L domain. Figs. 4A-4B show the construction of the retroviral vector constructs.
Figs. 5A-5H illustrate expression of (chimeric-) TCR constructs on primary human T lymphocytes. Expression of ( ) chimeric single chain TCR VαVβCβς, (ii) chimeric two chain VαCας /VβCβζ5 and (Hi) full-length TCR αβ constructs was determined by flow cytometry after gene transduction of primary human T lymphocytes. Events shown represent viable lymphocytes stained with anti-Vα12.1FITC and anti-Vβl PE.
(5A): Human T lymphocytes transduced with the CD24 gene (negative control). (5B):
HLA-A1 restricted, MAGE-1 specific parental CTL clone MZ2-82/30 (positive control).
(5C): Human T lymphocytes transduced with VαVβCβ-ς retroviral vectors. (5D):
Human T lymphocytes transduced with V VβCβ-ς retroviral vectors and enriched by flow sorting using anti-Vα12.1 FITC and anti-Vβ-1 PE mAbs. (5E): Human T lymphocytes transduced with VαCα-ζ and VβCβ-ς retroviral vectors simultaneously. (5F): Human T lymphocytes transduced with VαCα-ς and VβCβ-ς retroviral vectors and followed by enrichment by flow sorting using anti-Vα12.1 FITC and anti-Vβ-1 PE mAb. (5G): Human T lymphocytes transduced with full-length TCR α and β retroviral vectors simultaneously. (5H): Human T lymphocytes transduced with full-length TCR α and β retroviral vectors, followed by Vα12.1 immunomagnetic selection and a second enrichment by flow sorting using soluble multimeric HLA-Al/MAGE-l/StrepPE complexes.
Fig. 6 shows that chimeric (scFv)-TCRγ or ζP0S T lymphocytes are able to specifically bind to soluble multimeric HLA-al/MAGE-1 complexes. Complexes with an irrelevant peptide derived from influenza virus nucleoprotein were not bound by the chimeric (scFv)-TCRγ or ζros T lymphocytes.
Fig. 7 shows that peptide pulsed target cells are lysed by (chimeric-) TCR
transduced human T lymphocytes. MAGE-1 peptide-pulsed HLA-Alpos target cells were incubated with the indicated human T lymphocytes and tested in a 6-h 51Cr release assay. Left row and middle row show the data using 51Cr labeled HLA- Alpos, MAGE-lneg EBV transformed B cell lines 72-2 and APD respectively, pulsed with MAGE-1 or Influenza virus peptides (10 μg/ml). The right row shows the data using 51Cr labeled HLA-A1P°S, MAGE-lneg MEL 2A melanoma cells pulsed with MAGE-1 or influenza virus peptides (10 μg/ml). Experiments were performed in triplicate, and the SD did not exceed 10%. The per cent specific 51Cr release is shown at different E:T ratios.
Figs. 8A-8E shows that native HLA-A1P0S, MAGE-1P0S melanoma cells are susceptible to lysis by (chimeric-) TCR transduced T lymphocytes. Cytotolytic capacity of human T lymphocytes was determined in 6-h 51Cr release assays. Left two rows show results obtained with 51Cr labeled HLA-Alpos, MAGE-lros melanoma cells (MZ2-MEL 3.0 and 518A2). The right row shows results obtained with control 51Cr labeled HLA-A1NEG, MAGE-1NEG melanoma cells (MEL 78 — , BLM - - - -) and renal cell carcinoma cells (SKR17 cl4 ). Anti-HLA-ABC (10μg/ml, ) or mouse Ig
(10μg/ml ) was added to the target cells 15-30 min. prior to incubation with the effector T lymphocytes ( — , no mAb). Shown are mean percentages of triplicates of per cent specific 5ICr release. Data of one representative experiment out of 3 are shown.
Fig. 9 shows that soluble multimeric HLA-A1 /MAGE-1 complexes identify functional CTL expressing retroviral introduced chimeric 3D scFv-TCR and chimeric tc-TCR and full-length TCR αβ transgenes Functional characteristics of human T lymphocytes were determined in flow cytometry and 51Cr release assays as described in materials and methods. (A): Flow cytometric analysis of human T lymphocytes incubated with soluble HLA-Al/MAGE-l/StreptavidinPE complexes (Al/Ml) and StreptavidinPE (StrepPE) was performed. (B): Cytotoxicity of human T lymphocytes against HLA-A1P0S, MAGE-1P0S melanoma cells and peptide pulsed HLA-Alpos, MAGE-1NEG EBV transformed B cells was analysed in a 6-h 51Cr release assay. The
HLA-A1P0S, MAGE-1P0S melanoma cell was incubated with the human CTL ( ).
Anti-MHC class I mAb was added (10 μg/ml, ) to the target and effector cell mixture to demonstrate HLA-Al/MAGE-1 specificity of lysis. The 51Cr labelled HLA-A1P0S EBV transformed B cell line APD was pulsed with MAGE-1 peptide (10 μg/ml, , no peptide: ). (C): Flow cytometric analysis of the human T lymphocytes using anti-Vα^.l*1170 and anti-VβlPE mAbs.
DETAILED DESCRD7TION OF THE INVENTION
The present invention relates to chimeric TCR receptors constructed from the variable regions of the TCR, in particular in the single chain design [(scFv)-TCR], the generation of immune-specific cells such as T lymphocytes, non-T lymphocytes, NK cells, monocytes or macrophages by transfecting these cells with chimeric (single or two gene(s)) T cell receptors. The targeting of antigen-specific/ non-specific immune cells
According to the present invention, chimeric TCRs are constructed by chimerizing the sequenced and cloned scFv-TCR or two-chain-Fv-TCR to any signal transducing molecule selected from immune cells, such as, but not limited to, CD2, CD3, CD 16, CD28, γ-chains, ζ-chains, KIR, KAR or fragments thereof, etc., and by molecular engineering and subsequently transfecting human or non-human immune cells (specific or non-specific) with genes encoding for scFv chimeric TCR. The invention is useful to identify whether target cells express the antigen for which the chimeric TCR is specific. The present invention is also useful when it is desirable to use the immune cells expressing the scFv-TCR or tcFv-TCR for immunotherapy of cancer, infectious diseases and autoimmune diseases, including rheumatoid arthritis.
Thus, the present invention provides techniques enabling one with ordinary skill to graft immune cells with chimeric scFv-TCR or tcFv-TCR specificity at will. The purpose of transfecting said immune cells is to make the cells specific towards target cells. That is, the transfected immune cells of the present invention are triggered as a result of binding of the scFv-TCR or tcFv-TCR to provide a specific biological action such as, but not limited to, targeted antigen uptake and presentation (antigen-processing cells), target cell cytotoxicity (T lymphocytes, NK cells, monocytes, etc.), lymphokine or cytokine production (Helper T cells), Ig production (B lymphocytes and plasma cells), and antigen-presenting functions (T cells, B cells, monocytes, macrophages).
The present invention creates target cell antigen-specific immune and non-immune cells to identify on mammalian cells the MHC-restricted antigenic structure(s) recognized by the relevant chimeric scFv-TCR or tcFv-TCR. Generally, a suitable antigen for the purposes outlined here in the present invention is any antigen or target cell membrane expressed molecules against which a T cell response can be mounted in vitro or in vivo or for which such a scFv-TCR or tcFv-TCR can be selected. Representative examples of
suitable antigens include, but are not limited to, viral antigens, synthetic antigens, tumor-associated antigens (TAA), tumor-specific antigens (TSA), MHC molecules (class I and class II) or autologous antigens. A hallmark of the present invention is that it allows the grafting of the MHC-restricted specificity to immune cells chimerized with a signalling element from immune cells, thereby triggering biological activities in the recipient immune cells following interaction with the relevant target cells. Moreover, chimeric scFv-TCR or tcFv-TCR with specificity for MHC non-restricted antigens such as, but not limited to, mucosal antigens and superantigens, can be deived from natural sources such as PBLs, tumor-infiltrating T cells or cloned cytotoxic T cells or cell lines, or can be derived from TCR V-gene segments created synthetically, chimerized to said signal transducing molecules and transfected into these immune cells.
Autologous, allogeneic or xenogeneic cytotoxic T lymphocytes (CTL) can often be generated against 'non'- or weak lymphocytes, TAA, TSA or viral epitopes, differentiation antigens or other (glyco) proteins. On the other hand, antigens which have mutated can act on natural TCR as antagonists to inhibit the CTL response to the wild-type epitope. This leads to T cell anergy and, hence, lack of a host immune response to either tumor TAA, TSA, or virus, leading to e.g., a tumor cell growth or viral persistence. Existing technology now allows the creation of peptides and their presentation to T lymphocytes, antigen-presenting cells, resulting in subsequent effective T lymphocyte response. The present invention provides (1) selection of scFv- or tcFv-TCR-DNA from natural sources such as PBLs, tumor-infiltrating T cells or cloned cytotoxic T cells or cell lines, or derived from TCR V-gene and, optionally, extracellular C, segments created synthetically, (2) cloning of these scFv- or tcFv-TCR-DNA, and (3) their chimerization to signalling structure and their transfection into immune cells. The present invention allows the use of said modified immune cells in adoptive in vivo gene and/or immunotherapy, to combat cancer, virus infections, or autoimmune diseases. Regarding organ or tissue graft or auto-reactive cells, chimeric scFv-TCR or tcFv-TCR reactive with TCR epitopes on host T cells which cause autoimmunity or graft rejection can be transfected in the host T cells for elimination of the reactive cells following in vivo transfer. In practice, a wide range of cloned TCR genes chimerized to genes encoding for immune cell signalling molecules with the requisite specificities can be generated by a person having ordinary skill in this art, cloned into the genome of viruses or other vectors and, with existing technology, introduced into host T cells for autologous
adoptive gene transfer and/or immunotherapy.
The chimeric TCR may also be complexed to the immune cells by chemical, physical and/or immunological means by a person having ordinary skill in the art. It is possible that one with ordinary skill may generate MHC negative immune cells to serve as recipient cells for scFv or tcFv chimeric TCR transfection so, that they can be used as universal immune cells for adoptive gene and/or immunotherapy.
The present invention relates to the functional expression of a cloned scFv-TCR or tcFv-TCR DNA or gene which has been chimerized to signal transducing elements derived from natural sources such as PBLs, tumor-infiltrating T cells or cloned cytotoxic T cells or cell lines into mammalian immune system cells. The invention is applicable to situations where it is desirable to have immune cells with a predetermined specificity in order to, e.g., investigate whether mammalian cells express the relative ligand for that chimeric TCR or introduce these chimeric TCR-expressing cells into immune cells of mammals that suffer from cancer, infectious disease or autoimmune diseases. The present invention also provides techniques to identify whether particular antigens against which said TCR are directed, are expressed by mammalian cells in vitro or in vivo. For these and other purposes the invention provides for MHC-restricted antigen-specific immune cells that (following introduction of a scFv- or tcFv- chimeric TCR-gene into these cells) functionally express these receptors on their surface and endows the cells with a predetermined antigen specificity. The antigen-binding substance can be selected from TCR, fragments of TCR and antigen-binding peptides other than antibodies.
The antigen named MAGE-1 (melanoma-associated neoplastic protein) codes for antigens recognized by autologous T lymphocytes on a melanoma tumor. These genes are not expressed in normal tissues except for testis. They are expressed in many tumors of several histological types. Also differentiation antigens coded by genes such as tyrosinase are recognized on human cancer cells by autologous CTL. The identification and characterization of these and other human tumor or viral infected and other tissue cells open the possibility for the systemic approach to specific immunitherapy with the engineered immune cells provided by this invention.
It is important to realize that tumor specific neo-antigens are easily tolerated by the immune system, equivalent of a tissue specific antigen. Therefore, only if tumor specific neo-antigens are effectively processed and presented in vivo or in vitro, will it serve as a
dominant target for T lymphocyte immunity. Whether or not a tumor-specific neo-antigen is immunogenic also depends on which tissue type and in what context it is expressed.
When a TAA is identified, characterized and cloned, it can be introduced in different tissue types so that it becomes immunogenic and specific T lymphocyte immunity can be generated against it (natural sources). ScFv- or tcFv-TCR as described in this invention can also be derived from natural sources such as PBLs, tumor infiltrating T-cells or cloned cytotoxic T cells or cell lines or can be derived from TCR V-gene and, optionally, extracellular C-gene, segments created in part or completely synthetically, chimerized to signal transducing elements selected from immune cells and then introduced into immune cells.
Table 1 herein shows examples of TCR and their tumor cellular ligands. TCR with specificities are possible candidates for use within the present invention or any system of the epitope specificity. Tumor antigens, viral antigens, MHC-antigens, differentiation antigens, autoimmune antigens and superantigens can be identified using T lymphocytes. T lymphocytes are the critical mediators of tumor specific rejection. Consequently, a wide variety of potential tumor antigens and other antigens recognizable by T cells are applicable. These chimeric scFv-TCR gene-transduced immune cells can be used for in vivo immunotherapy of cancer, infectious diseases or autoimmune diseases as described, or for the identification of relevant ligands on other mammalian cells. Thus, the present invention provides an immune cell having predefined biological specificity, wherein said immune cell is grafted with a chimeric T cell receptor. Generally, the immune cell of the present invention may be made from any human or non-human immune cell. Representative examples of immune cells include T lymphocytes, non-T lymphocytes, B cells, monocytes, macrophages, dendritic cells, NK cells plasma cells and Helper T cells. The immune cell may be either a specific immune cell and a non-specific immune cell.
In a preferred embodiment of the present invention of the mutated immune, the chimeric T cell receptor is a chimera between a single chain Fv-TCR or a two-chain Fv-TCR and a signal transducing element of an immune cell. Representative examples of signal transducing element include CD2, CD3, CD16, CD28, γ-chains, ε-chains, ς-chains, KIR, KAR and fragments thereof.
There are various preferred embodiments of the present invention. For example, the immune cell could be of an antigen processing and presenting cell, immune cell and the
predefined biological specificity is targeted antigen uptake and presentation. Another embodiment of the present invention provides an immune cell wherein the immune cell is T lymphocyte, B cell macrophage or a monocyte and the predefined biological specificity is target cell cytotoxicity. The immune cell can be a helper T cell or other immune cell and the predefined biological specificity is increased lymphokine or cytokine production.
An alternate form of the immune cell of the present invention is a B lymphocyte or a plasma cell and the predefined biological specificity is increased immunoglobulin production. Another alternate form of the immune cell is a mutated T cell, B cell, monocyte or macrophage and said predefined biological specificity is increased antigen presenting functions.
In another embodiment, the immune cell is a NK cell or lymphokine activated cell (LAK), which upon expression of the chimeric TCR can recognize and specifically kill the desired target cell. A chimeric receptor based on the killing activating receptor (KAR) or killing inhibitory receptor (KIR) may have very important applications using NK cells. In another embodiment, the present invention provides a target cell antigen-specific immune cell, said immune cell containing an antigen-binding molecule chimerized to a signal transducing element. The antigen-binding molecule may be selected from the group consisting of, but not limited to, T cell receptors, T cell receptor fragments or any protein recognizing and binding to MHC-presented peptides. In a preferred version of this embodiment, the antigen-binding molecule is a chimeric T cell receptor. Most preferably, the chimeric T cell receptor is a 2D or 3D scFv or a tcFv chimeric TCR.
In the target cell antigen-specific immune cell of the present invention, the antigen-binding molecule binds to a mammalian cell in a MHC restricted fashion or a MHC non-restricted fashion. In the target cell antigen-specific immune cell, the signal transducing element is selected from the group consisting, but not limited to, CD2, CD3, CD16, CD28, γ-chains, ε-chains, ς-chains, KIR, KAR and fragments thereof.
In the target cell antigen-specific immune cell of the present invention, the antigen-binding molecule binds to an antigen selected from the group consisting of viral antigens, synthetic antigens, tumor associated antigens, tumor specific antigens, mucosal antigens, superantigens, differentiation antigens, auto-immune antigens, class I major histocompatibility complex molecules, class II major histocompatibility complex molecules and epitopes of antigen-specific T cell receptor or antibodies.
It is specifically contemplated that pharmaceutical compositions may be prepared
using the novel immune cells of the present invention. A person having ordinary skill in this art would readily be able to determine, without undue experimentation, the appropriate dosages and routes of administration of the novel pharmaceutical composition of the present invention. Accordingly, the present invention also provides for a pharmaceutical composition comprising the immune cells of the invention. The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier as is well known in the art.
The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.
EXAMPLES
MATERIALS AND METHODS
Cells and antibodies.
T lymphocytes derived from healthy donors were isolated and expanded as described elsewhere (Wejtens et al.,1996). Target cell lines used in this study are: (i) the HLA-A1P0S, MAGE-1P0S melanoma cell line MZ2-MEL.3.0, (ii) the HLA-Alpos, MAGE-1NEG melanoma cell line MZ2-MEL 2.2 (kindly provided by T. Boon and P. Coulie, Brussels, Belgium), (Hi) the HLA-Alpos, MAGE-1P0S melanoma cell line 518A2 (kindly provided by P. Schrier, Leiden, the Netherlands), (iv) the HLA-Alpos, MAGE-1NEG melanoma cell line Mel 2A, (v), the HLA-A1NEG melanoma cell line MEL 78 . (vϊ) the HLA-A1NEG melanoma cell line BLM, (vii) the HLA-A1NEG renal carcinoma cell line SKR17-4 and (viii) the HLA-AlPOS EBV transformed B cell blasts APD and 72-2 ( kindly provided by P. Traversari, Milan, Italy) . The human embryonic kidney cell line 293T (kindly provided by Y. Soneoka, Oxford, UK; 20) was used as packaging cell line for the pSTITCH αζ/βζ anα" pBullet VαVβCβζ retroviral vectors (Weijtens et al., 1998). The mouse packaging cell line PG13 (ATCC CRL-10686) was used to obtain stable full-length TCR αβ retrovirus producing cells. The CTL clone MZ2-82/30 was used for isolation of RNA coding for the HLA-A1 restricted, MAGE-1 specific TCR (kindly provided by T. Boon and P. Coulie, Brussels, Belgium ); The mAbs used in this study were: anti-HLA-ABC (clone W6/32, Sera-Lab, Crawley Down, UK),
anti-CD4CY"3, anti-CD8FITC/PE (Becton Dickinson Biosciences, San Jose, USA) and the TCR Vα and Vβ family specific mAb anti-Vα12.1 (T Cell Diagnostics, USA) and anti-Vβl (Coulter-Immunotech, Marseille, France).
Retroviral (chimeric-) TCR gene transduction into primary human T lymphocytes: in vitro expansion of transduced T lymphocytes.
Activated human Peripheral Blood Lymphocytes (PBL) (5 x 106) were transduced using the pSTITCH or pBullet retroviral vector with the chimeric two chain TCR αζ/βζ genes or chimeric single chain TCR VαVβCβζ respectively, as described earlier (Weijtens et al., 1998). Briefly, anti-CD3 activated lymphocytes were incubated for 72 hrs with an irradiated (25 Gy) monolayer of recombinant retrovirus-producing 293T cells, using culture medium (RPMI 1640 with 25 mM HEPES, 10% human serum, 2mM Glutamine, Penicillin 100 U/ml and streptomycin 100 μg/ml) supplemented with 4μg/ml polybrene (Sigma, St. Louis, U.S.A.), and 360 IU/ml rIL-2 (Proleukin; Chiron, Amsterdam, the Netherlands). Retroviral transduction with full-length TCR αβ genes was performed with supernatant produced on PG13 packaging cells containing both pBullet TCR α and TCR β vectors essentially as described (Van de Griend et al., 1984). Expansion of transduced primary human T lymphocytes was performed in the presence of feeder cells as we described elsewhere (Van de Griend et al. 1984; Pollok et al., 1998).
Immunofluorescence analysis and sorting of retroviral transduced human T lymphocytes.
Cells (5 x 105) were stained with TCR Vα and Vβ family-type specific anti-Vα-tt.l1^0 (2 μg/ml) and anti-Vβ-lPE (2 μg/ml) mAb in a volume of 50 μl. The dotplots show viable T lymphoblasts selected by gating on forward (FSC) and sideward (SSC) light scatter signals. Analysis was performed on a FACSCAN instrument (Becton Dickinson Biosciences, San Jose, USA). Flow sorting was performed on a F ACS- Vantage instrument (Becton Dickinson Biosciences) using saturating concentrations of anti-Vα-π.l™0, anti-Vβ-lPE or Multimeric HLA-A1 /peptide/ streptavidinPE complexes (1:10 dilution of fresh preparations).
Cytotoxicity assays.
Cytolytic activity of transduced T lymphocytes was measured in 6 hr 51Cr-release assays
as described (Weijtens et al., 1998). In experiments aimed at blocking specific cytolytic activity, mAbs were added to the CTL, 15-30 min before addition of the target cells (W6/32: 10 μg/ml, or irrelevant mlg: 10 μg/ml). Peptide loading of the target cells was performed by addition of 10 μg/ml MAGE-1 nonapeptide (EADPTGHSY) or irrelevant Influenza peptide derived from Influenza virus A nucleoprotein (CTELKLSDY) to the target cells prior to incubation with effector T lymphocytes.
GM-CSF, TNFα and IFN-γ production.
To quantify GM-CSF and TNFα production by the gene-transduced T lymphocytes after antigen-specific stimulation, 6xl04 transduced PBL were cultured for 24 h either in the presence or absence of 2xl04 adherent tumor cells in RPMI-1640 medium supplemented with 360 IU/ml rIL-2. At the end of culture, supernatant was harvested and levels of TNF-α , GM-CSF (Medgenix, Fleurus, Belgium) and IFN-γ (CLB, Amsterdam, the Netherlands) were measured by standard ELISA according to the manufacturers instructions.
EXAMPLE 1
Isolation and cloning of a MAGE-1 specific (scFv)-TCR from the CD8+ CTL clone
82/30. Standard cloning techniques were used in the examples below. Techniques are described in: Molecular Cloning; A Laboratory Manual (Cold Spring Harbor Press, Cold Spring Harbor, N.Y.) by Maniatis, T. et al. or in cited publications. Cloning of the TCR Vp
The TCR is a heterodimer which consists of an α and a β chain. The TCR and β chains are members of the immunoglobulin gene superfamily and are generated by combined associations of V, J, D and C genes. The TCR polypeptides are disulfide linked, highly polymorphic in their N-terminal, variable domains and responsible for antigen recognition. Obtaining the TCR from the MAGE-1 specific CTL clone 82/30 (Traversari, C. et al., 1992) was achieved by PCR (Maniatis, T. et al.) amplification of cDNA obtained from this CTL clone.
To obtain cDNA, total RNA was isolated from T cell clone 82/30 cells according to the method by Chomczynski et al. (Chomczynski, P. and Sacchi, N., 1987) and transferred into cDNA essentially as described by Maniatis et al. Amplification of cDNA
sequences by PCR is possible only if the sequence of the gene of interest is known. In general, for PCR, two primers complementary to the 5' end and the 3' end of the sequence are used as the initiation point of DNA synthesis. Because the sequence of the 5' ends of the TCR and β chain from T cell clone 82/30 were unknown, a PCR method, referred to as RACE (rapid amplification of cDNA ends) was used to amplify the TCR α chain (Edwards et al., 1991). The TCR β chain was amplified by RACE-PCR using primers described in Table 2.
Oligonucleotide primers used to synthesize the and p chain cDNA and amplify the Vα, Vβ and Cβ gene segments (Table 2)
A fragment of about 350-450 base pairs was isolated from the agarose gel, purified and ligated into pBluescript (Stratagene, USA) as described by Maniatis et al. The ligation mixture was introduced into bacteria which were selected and expanded. DNA was isolated from these selected bacterial colonies and analyzed by restriction enzyme digestion to confirm the presence of the amplified TCR β fragment.
Three positive colonies were subjected to DNA sequencing. The sequences of these three individual clones were compared and found to be identical. The sequence obtained from the amplified TCR β fragments however did not include the signal sequence of the TCR β gene. To obtain the complete sequence of the TCR-V β gene, this partial sequence was compared with all known TCR β sequences. Alignment of the sequences showed almost 100% homology to sequences from the TCR β family 1 (TCRβ.l) (Hanspeter Saluz and Jean-Pierre Jost, 1989). Based on this sequence homology, a primer was synthesized complementary to the 5' end of the TCR β.l and used to amplify the complete TCR variable β.l 1987). Analysis of the obtained sequence showed 100% homology of the amplified TCR β fragment to the signal sequence and major part of the variable region of the TCR β chains from the TCR β family 1. Based on this sequence primers were designed that allowed cloning of the TCR variable β chains in a single chain TCR construct.
EXAMPLE 2
Cloning of the TCR α chain
For cloning of the TCR α chain, a different approach was followed. First, to determine to which family the TCR Vα chain belongs, a family typing PCR (Thor Straten,
P. et al. 1994) was performed. Twenty-one different TCR variable α chains have been described. In a family typing PCR, the template cDNA was divided into separate samples that are each individually amplified with a family specific 5' primer and a constant primer. Multiple PCR reactions had yielded amplified fragments. In order to determine which fragment corresponded to the TCR Vα fragment, a Southern blot was performed (Maniatis et al.) with a 32P-labeled Cα probe. A positive signal was observed only in the PCR reaction which was performed with the TCR α primer corresponding to family number 12. The rest of the DNA of this PCR reaction was purified with primer removal as described above and subjected to DNA sequencing. The obtained sequence was compared to the TCR α sequence of the only known member of family number 12 (Sim et al., 1984; Berkhout et al., 1998). Except for the diversity region, 100% homology was observed. This allowed the design of primers which could be used for the amplification of the complete variable region of the TCR α chain. The sequences of Vα and Vβ of the TCR derived from CTL clone 82/30 are shown in Figs. 2 A and 2B, respectively.
EXAMPLE 3
Construction of chimeric two domain and three domain single chain TCR/γ or ς molecules.
Construction of two domain single chain TCR/γ or r molecules. For construction of chimeric single chain TCR/γ or ζ molecules, a cloning vector was designed that allows easy construction of single chain molecules. The vector was made by replacement of the multiple cloning sites in pBluescript (Stratagene) by a specially designed poly linker (Table 3). For cloning of the TCR Vα and TCR Vβ fragments, primers were designed that allowed cloning of these fragments in front of the flexible linker sequence or after the linker sequences (Fig. 2).
For amplification of the TCR Vα and TCR Vβ fragments, two separate PCR reactions were performed to generate fragments that include the signal sequence of the V region and fragments that start practically at the beginning of the mature protein. The DNA fragments were digested with restriction enzymes that allow cloning next to the flexible linker. Positive bacterial colonies were grown for DNA purification and DNA was subjected to DNA sequencing. DNA clones with the correct sequence were used to construct the chimeric single chain TCR constructs. The clones containing either the TCR Vα or the TCR Vβ fragments in front of the flexible linker sequence were then ligated to
the TCR Vα and TCR Vβ fragments which lack the signal sequence. In this way, three different single chain TCRs were constructed (Vα-212 linker-Vβ, Vβ-212 linker-Vα and Vα-(Gly4Ser)3, linker-Vβ), see Figure 3.
For ligation of the two domain single chain TCR to γ or ς molecules, Bam HI and Xho 1 digested human γ and ζ DNA fragments were ligated 3' to the two single chain TCR constructs. The following chimeric two domain single chain TCR γ and ς constructs were made: Vα-212 linker-β-γ Vα-212 linker-β-ς, Vα-(Gly4Ser)3Nβ-γ, Vβ-212 linker-Vα-γ and Vβ-212 linker Vβ-ς.
Construction of three domain (3D) TCRγ or r molecules For the construction of chimeric three domain (3D) single chain TCR molecules the constant β chain domain was amplified by PCR from cDNA obtained from CTL 82/30 and inserted next to the chimeric single chain TCR Vα-212 linker-Vβ. The primers used to amplify the Cβ region are described in Table 4. The 3D TCR Vα-212 linker-Vβ-Cβ fragment was then reamplified by PCR with primers that introduced restriction sites allowing cloning into a retroviral pBullet expression cassette. The primers used for reamplification are described in Table 5.
Construction of chimeric two chain TCR/r molecules
For the construction of chimeric two chain TCR ζ molecules, RNA isolated from CTL clone 82/30 was amplified using Vα-ATG and Cα-cys primers and Vβ and Cβ-cys primers respectively. (Table 5). To construct the VαCς and VβCβζ genes (αζβζ). VαCα and VβCβ were each ligated 5' to the ς gene in pBluescript. Correct sequences of chimeric
VαCα and VβCβ constructs were then cloned into the pSTITCH retroviral vector.
EXAMPLE 4
Cloning of the two domain (scFv)-TCR-γ into the retroviral vector SFG and generation of stable virus producing packaging cells.
The chimeric single chain Vβ-212 linker-Vα_γ construct was ligated into the SFG retroviral vector (Figure 4) by standard cloning techniques. For the generation of virus producing amphotropic packaging cell lines the
SFG-Vβ-212-Vβ-γ retroviral vector was electroplated into the amphotropic packaging cell line PA317, using the BTX electro cell manipulator 600 (settings: 760 uF, 250 V, 129 Q)- PA317 cells expressing the Vβ-212-Vβ-γ chain were selected by a monoclonal antibody
directed against the Vα chain (Diversi-T0" Vα12, T cell Diagnostics, Cambridge, USA) bound to goat anti-mouse coated magnetic particles. The packaging cells containing the SFG-Vβ-212-Vα-γ construct were used to transduce anti-CD3 activated human PBL.
Cloning the chimeric three-domain scFv TCRγ or ζ into the retroviral pBullet cassette.
For expression of chimeric three domain single chain Ig/ γ or ς and TCR/γ or ς molecules in human T lymphocytes, the retroviral vector pBullet_was constructed. After removal of two Nco I sites (positions 316 and 3952) and the Xho I site (position 3834), in the retroviral vector pSTITCH (Weijtens, M.E.M., et al. 1998) a multiple restriction site sequence was introduced. The resulting vector was named pBullet. Into the Nco I site at position 1968 and the newly introduced Xho I site of pBullet an expression cassette sequence was introduced containing the signal sequence from the G250 mAb Variable heavy chain, two cloning sites for introduction of the three domain single chain TCR and a signal transducing element. Two signal transducing elements have been introduced: one containing a short constant Ig kappa chain sequence Ck, extracellular domain of ς, the CD4 transmembrane domain and the intracellular domain of the γ chain. The other signal-transducing element comprises the complete ζ, chain, starting at the Bam H I site present in r. The chimeric three domain TCR construct which were reamplified with primers shown in Table 5, were cloned into the pBullet vector containing the expression cassette. Sequences of the complete chimeric 3DTCR CkCD4Tmγ and 3DTCR/ς, were verified.
Generation of stable packaging cell lines containing the three domain TCR/γ or r constructs. For the generation of stable packaging cell lines producing the three domain
TCR/γ or ζ viruses PG13 packaging cells were cocultivated for two days with irradiated 293T cells (25 Gray), transfected with a: the retroviral vector pBullet 3D/CkCD4Tmγ or pBullet 3D/ς b: the amphotropic envelope construct pEUT 456 and c: the GAG-POL construct pHIT 60. PG13 packaging cells expressing the three domain TCRγ or ς construct, determined by flow cytometry using anti- Vα12.1 and anti-Vβl mAb, were selected by flow cytometric sorting. The efficiency of retrovirus production by PG13 packaging cell lines PG13-3DCkCD4Tπ_γ and PG13-3Dς was determined by applying serial dilutions of viral supernatant to 293T cells, which were analyzed two days later
for the percentage of Vα12.1pos, Vβlpos cells. Stable high producer PG13 packaging cells were used to produce viral supernatant used to transduce anti-CD3 activated human PBL.
EXAMPLE 5
Infection and expression of the chimeric (scFv)-TCRγ or r . in T cells.
To obtain optimal numbers of dividing T lymphocytes and optimal gene transduction, fresh or cryopreserved/thawed peripheral blood mononuclear cells (PBMC) from healthy donors were activated using anti-CD3 monoclonal antibody (mAb) and recombinant interleukin-2 (IL-2). Retroviral transduction of chimeric TCR αζ/βζ gene constructs and chimeric (scFv)-TCRγ/ζ gene constructs was performed by incubating human T lymphocytes with 293T packaging cells that were transiently transfected with: (0 two retroviral vectors each comprising chimeric TCR αβ gene constructs; (ii) a vector containing the retroviral Gibon Ape Leukemia virus envelope and (iii) a vector containing the viral GAG and POL genes. The full-length TCR α and β genes were introduced into human T lymphocytes derived from a different donor by incubation with supernatant obtained from PG13 packaging cells that contain both full-length TCR α and β genes.
Flow cytometric analysis of gene-transduced T lymphocytes demonstrated expression of the chimeric-TCR αζ/βζ an^ chimeric 3D (scFv)-TCRγ or ζ transgenes in 25 to 40% of primary activated, human T lymphocytes as evidenced by the strictly coordinated reactivity with anti-TCR Vα-12.1 and anti-Vβ-1 family typing mAbs respectively Fig. 5 shows the expression of (i) chimeric single chain TCR VαVβCβζ, (ii) chimeric two chain VαCαζ /VβCβζ} and (iii) full-length TCR αβ constructs which was determined by flow cytometry after gene transduction of primary human T lymphocytes. Events shown represent viable lymphocytes stained with anti-Vα12.1Frrc and anti-VβlPE. (A): Human T lymphocytes transduced with the CD24 gene (negative control). (B): HLA-A1 restricted, MAGE-1 specific parental CTL clone MZ2-82/30 (positive control). (C): Human T lymphocytes transduced with VαVβCβ-ς retroviral vectors (D): Human T lymphocytes transduced with VαVβCβ-ς retroviral vectors and enriched by flow sorting using anti-Vα12.1 FITC and anti-Vβ-1 PE mAbs. (E): Human T lymphocytes transduced with VαCα-ς and NβCβ-ς retroviral vectors simultaneously. (F): Human T lymphocytes transduced with VαCα-ζ and VβCβ-ζ retroviral vectors and
followed by enrichment by flow sorting using anti-Vα12.1 FITC and anti-Vβ-1 PE mAb. (G): Human T lymphocytes transduced with full-length TCR α and β retroviral vectors simultaneously. (H): Human T lymphocytes transduced with full-length TCR α and β retroviral vectors, followed by Vα12.1 immunomagnetic selection and a second enrichment by flow sorting using soluble multimeric HLA-Al/MAGE-l/StrepPE complexes. FACS analysis using anti-Vα12.1 and anti Vβl show identical fluorescence signals as the 3D scFv TCR VαVβCβζ.
EXAMPLE 6 (Chimeric) (scFv)-TCRγ or r*°°s T lymphocytes bind soluble multimeric HLA-Al/MAGE-1 complexes.
The HLA-A1 binding MAGE-1 peptide EADPTGHSY and an irrelevant HLA-A1 binding peptide derived from Influenza virus A nucleoprotein (CTELKLSDY) were used to construct soluble peptide-MHC complexes for the identification of antigen specific TCR on gene transduced T lymphocytes. Tetrameric (or multimeric) complexes comprising soluble MHC class I molecules with antigenic peptides and PE conjugated streptavidin are reagents that allow the identification of MHC restricted, antigen specific T lymphocytes. Binding of tetrameric complexes has been shown to correlate with recognition of viral antigens presented by virally infected cells or tumor associated antigens presented on tumor cells by cytotoxic T cells (Cole et al., 1995). Tetramer binding T cells were shown to recognize and kill virally infected cells or tumor cells.
Construction of multimeric HLA-Al/MAGE-1 peptide and HLA-Al/Influenza virus A nucleoprotein peptide complexes:
First the HLA-A1 heavy chain was cloned by the following protocol: The gene coding for the HLA-A101 gene was amplified by PCR using the primers
GCGGCGGCGGCCATGGGCTCCCACTCCATGAGG and TTTCTGTGCATCCAGAA TATGATGCAGGGATCCGAGCTCCCATCTCAGGGT, and the product of this first PCR was used as template in a second PCR using the primers GCGGCGGCGGCCATGGGCTCCCACTCCATGAGG and CGGCAGGAGA GCGGCCGCTTAACGATGATTCCACACCATTTTCTGTGCATCCAGAAT. The restriction sites Ncol and Notl used for cloning are underlined. The forward primers encode the peptide HHILDAQKMVWNHR recognized by the BirA enzyme used for in vivo biotinylation (see below). The PCR products were ethanol-precipitated, digested with Ncol
and Notl enzymes, gel-purified and ligated into the plasmid pET21d (Novagen, Madison,USA) digested with the same enzymes. The plasmids were transformed into DH5α and clones containing an insert were sequenced. Clones with the correct sequence were then transformed into BL21DE3 for protein production, together with a compatible plasmid containing the Bir A gene under the control of the tac promoter (pBirCm, Avidity™, denvers, USA). The plasmid pHNβ2m was used to produce the β2m.
Next, the HLA-A1 protein and β2m protein were purified by inclusion body purification:
The inclusion body purification of HLA-A1 proteins was done by a 10-ml overnight bacterial culture was diluted in one liter of 2xTY containing 100 μg/ml ampicillin and 15 μg/ml chloramphenicol and incubated at 37°C with agitation. At OD600 of 0.5, ImM IPTG and 50 μM biotin was added and the bacterial culture was incubated at 37°C for 3-4 h. The bacterial culture was centrifuged and the pellet was resuspended in 20 ml of lysis buffer (25% sucrose, 1 mM EDTA, 50 mM Tris-Hcl pH 8). 200 μl of 100 mM PMSF in isopropanol and 1 ml of 10 μg/ml lysozyme were added and the bacteria were incubated 30 min on ice. 200 μl of IM MgC12, 20 μl of IM MnC12 and 20 μl of 10 μg/ml DNAsel were added and the mix was incubated again 20 min on ice. After sonication and centrifiigation 15 min at 10 000 rpm at 4<>C, the bacterial pellet was resuspended in 20 ml of detergent buffer (0.2 M Nacl, 1% DOC, 1% Nonindet P40, 2 mM EDTA, 20 mM Tris 7.5). 40 μl of IM DTT and 200 μl of 100 mM PMSF were added. After centrifugation (15 min 10000 rpm at 4°C) the pellet was resuspended by sonication and centrifuged again, and then resuspended in 12 ml of triton buffer (100 mM NaCl, 50 mM Tris-Hcl pH 8, 1 mM EDTA, 0.5% Triton X100) plus 24 μl of IM DTT. After centrifugation (15 min 10000 rpm at 4°C) the pellet was washed 2 more times in this buffer and finally resuspended in 2 ml of freezing buffer (20 mM Tris-Hcl pH 7.5, 150 mM NaCl, 10 mM DTT) and kept at -70°C.
Finally the HLA-A1 /peptide complexes were reconstituted by dilution: For reconstitution of HLA-Al/peptide complexes, the inclusion bodies were thawed, centrifuged for 10 min at 10 000 rpm, and the protein pellet was dissolved in the same volume of urea buffer (50% urea, 50 mM NaCl, 20 mM Tris 7.5, 5 mM reduced glutathion). After a 10 min centrifugation at 10,000 rpm, the supernatant was used for refolding. The complex formation was initiated by dilution of the two denatured subunits and peptide into 200 ml of refolding buffer (400 mM Arginine/Hcl, 2 mM EDTA, 5 mM
reduced glutathion, 0.5 mM oxidized glutation, 100 mM Tris-Hcl pH 7.5). The amount of heavy chain, β2m and peptide were respectively 6 mg, 5 mg and 2 mg. The solution was incubated without agitation for 36h at 4°C and then concentrated with Centriprep-10 from 200 ml to 700 μl. The concentrated protein was subjected to gel filtration on a Superdex 200 column (Pharmacia, Uppsala, Sweden) and the peak corresponded to 48 kDa was collected.
Multimeric HLA-Al/peptide/streptavidinPE complexes used for staining of transduced lymphocytes were made by mixing equal volumes of streptavidin PE (5 μg/ml, Becton Dickinson Biosciences, San Jose, USA) and soluble HLA-A1 /peptide (120 μg/ml), followed by 30 min incubation on ice. Chimeric (scFv)-TCRγ/ζ , were incubated for 30 min with 1:10 dilution of a fresh preparation of multimeric
HLA-Al/MAGE-l/StreptavidinPE complexes or HLA-Al/Influenza/StreptavidinPE complexes at 4°C
As shown in figure 6, MAGE-l/HLA-Al/streptavidinPE multimers specifically stained the genetically introduced chimeric two chain-ας/βζ } chimeric scFv TCR/ς and full-length αβ TCRs expressed on human T lymphocytes, but not control multimeric HLA-Alcomplexes presenting the Influenza peptide. Neither did control T lymphocytes, that were transduced with the enhanced green fluoresence protein (EGFP) transgene, recognize and bind soluble multimeric HLA-Al/MAGE-1 complexes. FACS analysis using multimeric HLA-Al/MAGE-1 complexes show identical fluorescence signals as the 3D scFv TCR VαVβCβζ.
EXAMPLE 7
Functional analysis of chimeric (scFv) TCRγ/ς ,POS T lymphocytes.
MAGE-1 peptide loaded target cells specifically trigger lysis by (i) chimeric 3D scFv-, (ii) chimeric tc- and (iii) full length-TCRPOS T lymphocytes.
To determine whether chimeric 3D scFv-, tc- and full length-TCRP0S T lymphocytes were able to recognize the MAGE-1 peptide, 51 Cr labeled MAGE-1NEG, HLA-Alpos melanoma cells (MEL 2A) and EBV transformed B cell blasts (72-2 and APD) were pulsed with 10 μg/ml MAGE-1 peptide or irrelevant Influenza virus peptide derived from Influenza virus A nucleoprotein. and incubated for 6 hour with the chimeric (scFv)-TCRp0S T lymphocytes T lymphocytes expressing chimeric 3D
scFv-TCRs , chimeric tc-TCRs and full-length αβ TCRs were indeed able to lyse the MAGE-1 peptide loaded, MAGE-1NEG/ HLA-A1P0S MEL 2A melanoma cells and the MAGE-1NEG/ HLA-A1P0S B-lymphoblastoid cell lines 72-2 and APD. Only MAGE-1 peptide-pulsed MAGE-1NEG/ HLA-A1P0S target cells were specifically lysed by the transduced T lymphocytes, but not the unloaded cells or cells loaded with the irrelevant Influenza peptide (Fig 7). Cytotoxicity analysis show that HLA-A1P0S, MAGE-1P0S melanoma cells are lysed by the 3D scFv TCR VαVβCβCCkCD4Tmγ p0S T lymphocytes as efficiently as by the 3D scFv TCR VαVβCβςpos T lymphocytes.
HOLA-Al™8, MAGE-l™8 melanoma cells specifically trigger lysis by chimeric (scFv)- TCR POS χ lymphocytes
Several 51Cr labeled HLA-A1P0S /MAGE-1P0S melanoma cell lines and control HLA-A1NEG cell lines were incubated with the chimeric 3D (scFv)-TCRP0S , tc-TCRP0S and full-length TCRP0S T lymphocytes to determine the HLA-A1 restricted, MAGE-1 specificity of the transduced T lymphocytes. As shown in Fig.8 sorted chimeric 3D scFv-TCRp0S, tc-TCRP0S and sorted-full-length TCRP0S T lymphocytes specifically lysed the HLA-A1P0S, MAGE-1P0S melanoma cells MZ2-MEL 3.0 and 518A2, but not the HLA-A1NEG control cell lines (MEL 78, BLM and SKRC17-4) in a 6 hour incubation period. Further proof of MAGE-1 specificity of transduced T lymphocytes came from the addition of anti-MHC class I mAb, which resulted in significant lower tumor cell lysis, whereas irrelevant mAb did not inhibit cytolytic activity (Fig 8).
Analysis of lymphokine production by chimeric (scFv)-TCRγ/ζ POS T lymphocytes.
HLA-A1 restricted, MAGE-1 specificity of the chimeric 3D scFv-TCRP0S, tc-TCRpos and full length TCRP0S T lymphocytes was analyzed by incubating these cells with MAGE-1 peptide pulsed HLA-A1P0S, MAGE-1NEG Melanoma cells MZ2-MEL 2.2 and HLA-A1P0S, MAGE-1P0S melanoma cells MZ2-MEL 3.0. After 24 hour incubation supernatant was harvested and analyzed for the presence of TNFα, GM-CSF and IFNγ. Table 6 shows the results of the incubation of the CTL with HLA-A1P0S, MAGE-1P0S melanoma cells and MAGE-1 peptide pulsed melanoma cells significant amounts of these lymphokines were produced.
Soluble multimeric HLA-Al/MAGE-1 complexes identify functional (i) chimeric 3D scFv-TCR, (ii) chimeric tc-TCR and (Hi) full length TCR expressing T lymphocytes.
Soluble mulimeric HLA-Al/MAGE-1/streptavidin complexes could be used to identify and select peptide specific cells from bulk cultured gene transduced T lymphocytes. Therefore, chimeric 3D scFv-TCR, chimeric tc-TCR and full-length TCR αβ gene transduced T lymphocytes were sorted with soluble multimeric HLA-Al/MAGE-l/streptavidinPE complexes. Positive and negative fractions obtained by sorting were expanded and analyzed for HLA-A1 restricted, MAGE-1 specificity. As shown in figure 9, CD8P0S chimeric 3D scFv-TCR, chimeric tc-TCR and full-length
TCR αβ gene transduced T lymphocytes enriched by soluble multimeric HLA-Al/MAGE-l/streptavidinPE complexes specifically lysed not only MAGE-1 peptide pulsed B-LCL target cells but also by the HLA-A1P0S, MAGE-1P0S MZ2-MEL 3.0 melanoma cells. The negative fraction obtained from these sorts; were not able to lyse the HLA-Alpos, MAGE-1P0S melanoma cells and only a weak response to peptide pulsed target cells was observed. Surprisingly, both the negatively and positively sorted Full-length TCR αβ gene transduced T lymphocytes express the introduced TCR αβ as determined by flow cytometry using family typing mAbs anti-Vα12.1Frτc and anti-VβlPE.
Table 1;
Antigens on Autologous Human Cancers Recognized by T Cell Responses
Antigen Tumor Type Normal Tissue Comments
Expression
MAGE-1 Melanoma, lung Testes Not expressed in melanocytes
MAGE-3 Melanoma, lung Testes Not expressed in melanocytes
Tyrosinase Melanoma Melanocytes Melanosomal protein
Albino
MUCI Pancreas, breast Epithelium Non-MHC restricted
Melan-A/ Melanoma Melanocytes Melanosomal protein
MART-1 and retina
PMell7/silver Melanoma Melanocytes Melanosomal protein and retina
GP100 Melanoma Melanocytes
Table 2.:
Oligonucleotide Primers
Vα-ATG: 5' GCG AAT TCT ACG TAC CAT GAA CAT GCT GAC TGC CAG C3< Vα-3 5' CGT CTA GAG GAC AGA AGG TAA CTC AAG CGC AG 3' Vβ-ATG: 5' CCG AAT TCT ACG TAC CAT GGG CTT CAG GCT GCT CTG 3> Vβ-3 5' GCG GAT CCG AGC ACT GTC AGC CGG GTG CC 3'
Table 3:
212 LINKER
5' GTA CGA ATT CGC AGA TCT GGC TCT ACT TCC GGT AGC AAA TCC TCT GAA GGC AAA GGT ACT AGT GCG GAT CCG GCT CGA GCA GCT 3> (GLYY.SER, LINKER
5' GAT CCG GTG GAG GCG GTT CAG GCG GAG GTG GCT CTG GCG GTG GCG GAT CGA 3'
Table 4: Primers used for amplification of the TCR β constant region and for reamplification of the three domain TCR Vα-212 linker-VβCβ fragment.
Cβ 5' primer: 5 -CTG-ACA-GTG-CTC-GAG-GAC-CTG-3'
Cβ 3' primer: 5 -CTC-TGG-ATC-CCG-TCT-GCT-CTA-CCC-CAG-GGG- TG-3'
Vα 5' primer for reamplification: 5'-GCG-AAT-TCT-ACG-TAC-CAT-
GGA-CAT-GCT-GA-TGC-CAG-C-3'
Cβ primer for reamplification: 5 -TTG-TTC-TGC-GGC-CGC-GTC- T"GC-TCT-ACC-CCA-GGC-3'
Table 5: Primers for reamplification of the three domain TCR fragment allowing introduction into the pBullet cassette vector.
TCR Vα 5' primer: 5'-TTA-CTC-GCG-GCC-CAG-CCG-GCC-ATG-GCC-CAG-
AAG-GTA-ACT-CAA-GCG-CAG-3'
TCR Vβ 3 5.-TTG-TTC-TGC-GGC-CGC-GAG-CAC-TGT-CAG-GGT- GCC-TG-3'
Table 6: Chimeric TCR expressing T cells undergo specific stimulation to produce cytokines
MAGE- 1 peptide pulsed melanoma cells *
A TNFα pg/ml GM-CSFpg/ml lFNγ pg/ml
No pept. + MAGE-1 pept. No pept. +MAGE-1 pept. No pept. + MAGE-1 pept
CTL 82/30 0.0 2996 0.0 426 39 6678 ch-scTCR VαVβCβζP0S 56 105 0.0 629 34 577
T lymph. ch-2c αζ/βζpos 61 380 0.0 3767 97 1954
T lymph. full-length αβpos 4.0 75 0.0 1924 91 1024
T lymph.
As described in materials and methods
References:
1. Berkhout, B., Hall, C. and Terhorst, C. 1988. Nature 11 pp. 5209.
2. Chomczynski, P. and Sacchi, N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Bioch. 162,pp.
156-159.
3. Cole, D.J., et al. 1995. Cancer Res. 55, p.748
4. Edwards, J.B.D.M., Delort, J. and Mallet, J. 1991. Nucleic Acids Res. 19 pp. 5227-5232. 5. Hanspeter Saluz and Jean-Pierre Jost. 1989. A simple high-resolution procedure to study DNA methylation and in vivo DNA-protein interaction on a single-copy gene level in higher eukaryotes. Proc. Natl. Acad. Sci. USA, 86, pp.2602-2607. 6. Kimura, N., Toyonaga, B., Yoshikai, Y., Du. Ran-Pan. and Mak, T.K. 1987. Eur. J. Immunol. 17, pp. 375-383. 7. Maniatis, T. et al., Molecular cloning; A laboratory manual. Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
8. Pollok, K.E., Hanenberg, H., Noblott, T.W., Schroeder, W.L., Kato, I., Emanuel, D., et al. 1998. J. Virol, 72, pp. 4882-4892.
9. Sim, G.K., Yagϋe, J., Nelson, J., Marrack, P., Palmer, E., Augustin, A. and Kappler, J. 1984. Nature 312, pp. 771-775.
10. Thor Straten, P., SchoUer, J., Hou- Jensen, K. and Zeuthen, J. 1994. Int. J. Cancer 56, pp. 78.
11. Traversari, C, Van der Bruggen, P., Luescher, I.F., Lurquin, C, Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A. and Boon, T. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176, pp. 1453-1457.
12. Van de Griend, R.J., Giphart, M.J., Van Krimpen, B.A. and Bolhuis, R.L.H. 1984. J. Immunology 133, pp. 1222-1228. 13. Weijtens, M.E.M., Willemsen, R.A., Valerio, D, Stam, K. and Bolhuis, R.L.H. 1996. J. Immunol. 157, pp. 836-843. 14. Weijtens, M.E.M., Willemsen, R.A., Hart, E.H. and Bolhuis, R.L.H. 1998. Gene Therapy 9, pp. 1195-1203.
Claims
1. An immune cell having predefined specificity, wherein said immune cell is either complexed with an antigen-specific MHC-restricted chimeric T cell receptor (TCR) or a fragment thereof, or transfected with an antigen-specific MHC-restricted chimeric TCR gene.
2. The immune cell according to claim 1, wherein said chimeric TCR comprises: (i) a first segment comprising either (a) a single-chain TCR (scFv-TCR) made of the variable (V) region and, optionally, of either the extracellular constant (C) region of an antigen-specific TCR, or of the constant region of the immunoglobulin kappa Ught chain (Ck); or (b) a two-chain TCR (tcFv-TCR) made of the extracellular variable (V) and constant (C) regions of an antigen-specific TCR; and (ii) a second segment comprising a signal transducing element of an immune cell.
3. The immune cell of claim 2, wherein said scFv-TCR or tcFv-TCR comprise the alpha and beta chains pair or the gamma and delta chain pair of an antigen-specific TCR.
4. The immune cell according to claim 2 or 3, wherein said single-chain TCR of the first segment comprises the variable (N) region of said antigen-specific TCR.
5. The immune cell according to claim 4, wherein said single-chain TCR of the first segment is a two-domain (2D) single-chain TCR made of the extracellular variable (N) region VoNβ chains of said antigen-specific TCR linked by a linker.
6. The immune cell according to claim 4, wherein said single-chain TCR of the first segment is a three-domain (3D) single-chain TCR made of the extracellular variable (V) and constant (C) regions of said antigen-specific TCR.
7. The immune cell according to claim 5, wherein said three-domain (3D) single-chain
TCR comprises the VαVβCβ or VoNβCα chains of said antigen-specific TCR.
8. The immune cell according to claim 4, wherein said single-chain TCR of the first segment is a three-domain (3D) single-chain TCR made of the extracellular variable (V) NαNβ chains of said antigen-specific TCR and the constant (C) region of the immunoglobulin kappa light chain (Ck).
9. The immune cell according to claim 2 or 3, wherein said first segment comprises a two-chain TCR (tcFv-TCR) made of the extracellular variable (V) and constant (C) regions of said antigen-specific TCR.
10. The immune cell according to claim 9, wherein said two-chain TCR (tcFv-TCR) comprises the VαCα + VβCβ chains of said antigen-specific TCR.
11. The immune cell according to any one of claims 1-6, wherein said second segment comprises a signal transducing element of an immune cell comprising the intracellular signaling unit alone or together with the transmembrane domain and optionally with the extracellular domain of signaling chains.
12. The immune cell according to claim 11, wherein said signal transducing element is selected from the group comprising the TCR/CD3 complex gamma, delta, epsilon, eta or zeta chain, the gamma chain of the Fc receptor, the alpha, beta and/or gamma subunit of the IL-2 receptor, the CD2, CD 16 and CD28 co-receptor chains, the signaling elements of the natural killer (ΝK) receptor, killing inhibitory receptor (KIR) or killing activating receptor (KAR), or any signaling element derived from an immune cell, and combinations of said signal transducing elements.
13. The immune cell according to claim 12, wherein said signal transducing element is selected from the group comprising the TCR/CD3 complex zeta chain or the gamma chain of the Fc receptor.
14. The immune cell according to any one of claims 1-13, wherein said immune cell is selected from the group comprising resting, activating and memory T lymphocytes, cytotoxic lymphocytes (CTLs), helper T cells , non-T lymphocytes, B cells, plasma cells, natural killer (ΝK) cells, monocytes, macrophages, eosinophils and dendritic cells.
15. The immune cell according to any one of claims 1-13, wherein said immune ceU is selected from the group consisting of antigen-specific immune ceUs and non-specific immune cells.
16. The immune cell according to any one of claims 1-13, wherein said immune ceU is an antigen-processing cell and said predefined specificity is targeted antigen uptake and presentation.
17. The immune cell according to any one of claims 1-13, wherein said immune cell is selected from the group consisting of lymphocytes, NK cells, macrophages, monocytes, eosinoph s and other cytotoxic cells and said predefined specificity is target cell cytotoxicity.
18. The immune cell according to any one of claims 1-13, wherein said immune cell is a helper T cell and said predefined biological specificity is increased lymphokine or cytokine production.
19. The immune cell according to any one of claims 1-13, wherein said immune cell is selected from the group consisting of B lymphocytes and plasma cells and said predefined specificity is increased immunoglobulin production.
20. The immune cell according to any one of claims 1-13, wherein said immune ceU is selected from the group consisting of T cells, B cells, monocytes and macrophages and said predefined biological specificity is increased antigen-presenting functions.
21. The immune cell according to any one of claims 1-13, wherein said immune cell is a target ceU antigen-specific immune cell containing an antigen-binding molecule selected from the group consisting of the alpha/beta chains or the gamma/delta chains of the antigen-specific T cell receptor, chimerized to a signal transducing element selected from the group comprising the TCR/CD3 complex gamma, delta, epsilon, eta or zeta chain, the gamma chain of the Fc receptor, the alpha, beta and/or gamma subunit of the IL-2 receptor, the CD2, CD16 and CD28 co-receptor chains, the signaling elements of the natural killer (NK) receptor, killing inhibitory receptor (KIR) or Wiling activating receptor (KAR), or any signaling element derived from an immune cell, and combinations of said signal transducing elements.
22. The target cell antigen-specific immune cell of claim 21, wherein said antigen-binding molecule binds to an antigen selected from the group consisting of viral antigens, synthetic antigens, tumor associated antigens, tumor specific antigens, mucosal antigens, superantigens, differentiation antigens, auto-immune antigens, class I MHC molecules and class II MHC molecules, and self antigens.
23. The target cell antigen-specific immune cell of claim 22, wherein said antigen-binding molecule binds to the melanoma-associated neoplastic protein (MAGE-1) antigen.
24. An immune cell complex according to any one of claims 1-23, wherein the chimeric antigen-specific TCR or TCR fragment is either bound to the immune cell by chemical conjugation or is bridged to the immune cell by a macromolecule or by a bispecific antibody binding both to the TCR or TCR fragment and to the immune cell.
25. The immune cell complex according to claim 24, wherein the macromolecule is avidin, streptavidin or polylysine.
26. The immune cell according to any one of claims 1-23, wherein said immune cell is transfected with said antigen-specific chimeric TCR gene.
27. A pharmaceutical composition comprising immune cells according to any one of claims 1-26.
28. The pharmaceutical composition according to claim 27, further comprising a pharmaceutically acceptable carrier.
29. The pharmaceutical composition according to claim 27 or 28 for the treatment of cancer, infectious diseases, autoimmune diseases or graft rejection.
30. The pharmaceutical composition according to claim 29 comprising the immune cells of claim 23 for the treatment of melanoma.
31. A method for treatment of a tumor in a patient comprising complexing lymphocyte cells of the patient with an antigen-specific MHC-restricted chimeric T ceU receptor (TCR) or a fragment thereof, or transfecting said autologous lymphocytes with an antigen-specific MHC-restricted chimeric TCR gene encoding a scFv-TCR which binds to an antigen associated with said tumor and a segment encoding a signal transducing element of an immune cell.
32. A method for treatment of melanoma in a patient comprising transfecting lymphocyte cells of the patient with an antigen-specific MHC-restricted chimeric T cell receptor (TCR) gene containing a segment encoding a scFv-TCR which binds to the melanoma-associated neoplastic protein (MAGE-1) antigen and a segment encoding a signal transducing element of an immune cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU12927/00A AU1292700A (en) | 1998-11-19 | 1999-11-18 | Immune cells having predefined biological specificity, comprising chimeric t cell receptor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12714298A IL127142A0 (en) | 1998-11-19 | 1998-11-19 | Immune cells having predefined biological specificity |
| IL127142 | 1998-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2000031239A1 true WO2000031239A1 (en) | 2000-06-02 |
Family
ID=11072157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IL1999/000622 WO2000031239A1 (en) | 1998-11-19 | 1999-11-18 | Immune cells having predefined biological specificity, comprising chimeric t cell receptor |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU1292700A (en) |
| IL (1) | IL127142A0 (en) |
| WO (1) | WO2000031239A1 (en) |
Cited By (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002013861A2 (en) * | 2000-08-11 | 2002-02-21 | Favrille, Inc. | Method and composition for altering a t cell mediated pathology |
| WO2002077029A2 (en) * | 2000-11-07 | 2002-10-03 | City Of Hope | Cd19-specific redirected immune cells |
| KR100388942B1 (en) * | 2000-07-08 | 2003-06-25 | 한화석유화학 주식회사 | A Single Chain Variable Fragment of an Antibody for Protein Expressed on Cell Surface of Human Cortical Thymocyte and Leukemic Cell |
| WO2004033685A1 (en) * | 2002-10-09 | 2004-04-22 | Avidex Ltd | Single chain recombinant t cell receptors |
| WO2004056845A2 (en) * | 2002-12-19 | 2004-07-08 | Johannes Gutenberg-Universität Mainz | Method for the production of a t cell receptor (tcr) consisting of a single chain tcr (sctcr) and a tcr constant region |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| WO2007073147A1 (en) * | 2005-12-20 | 2007-06-28 | Erasmus University Medical Center Rotterdam | Apoptosis-inducing protein complexes and therapeutic use thereof |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| WO2011140170A1 (en) * | 2010-05-04 | 2011-11-10 | Yeda Research And Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
| WO2013039889A1 (en) * | 2011-09-15 | 2013-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| EP3097923A1 (en) | 2007-01-31 | 2016-11-30 | Yeda Research And Development Co., Ltd. | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| WO2017123808A1 (en) | 2016-01-15 | 2017-07-20 | The J. David Gladstone Institutes | Methods of treating disease by metabolic control of t-cell differentiation |
| US9790278B2 (en) | 2012-05-07 | 2017-10-17 | The Trustees Of Dartmouth College | Anti-B7-H6 antibody, fusion proteins, and methods of using the same |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| JP2018046811A (en) * | 2011-09-29 | 2018-03-29 | エーピーオー‐ティー ビー．ヴイ． | Multispecific binding molecules targeting aberrant cells |
| CN107881185A (en) * | 2017-11-21 | 2018-04-06 | 重庆天科雅生物科技有限公司 | A kind of single-stranded TCR carrier Ts and single-stranded TCR T cells production technology |
| WO2018132739A2 (en) | 2017-01-13 | 2018-07-19 | Agenus Inc. | T cell receptors that bind to ny-eso-1 and methods of use thereof |
| WO2019046856A1 (en) | 2017-09-04 | 2019-03-07 | Agenus Inc. | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
| US10336804B2 (en) | 2004-09-24 | 2019-07-02 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| US10857181B2 (en) | 2015-04-21 | 2020-12-08 | Enlivex Therapeutics Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| US10946104B2 (en) | 2012-01-13 | 2021-03-16 | Apo-Tb.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11155786B2 (en) | 2015-01-23 | 2021-10-26 | Oslo Universitetssykehus Hf | Universal killer T-cell |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| WO2023047089A1 (en) | 2021-09-21 | 2023-03-30 | Oslo Universitetssykehus Hf | Binding proteins for terminal deoxynucleotidyl transferase (tdt) |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994029438A1 (en) * | 1993-06-11 | 1994-12-22 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| WO1996018105A1 (en) * | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| WO1997032603A1 (en) * | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
-
1998
- 1998-11-19 IL IL12714298A patent/IL127142A0/en unknown
-
1999
- 1999-11-18 WO PCT/IL1999/000622 patent/WO2000031239A1/en active Application Filing
- 1999-11-18 AU AU12927/00A patent/AU1292700A/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994029438A1 (en) * | 1993-06-11 | 1994-12-22 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| WO1996018105A1 (en) * | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| WO1997032603A1 (en) * | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
Non-Patent Citations (4)
| Title |
|---|
| CHUNG S ET AL: "FUNCTIONAL THREE-DOMAIN SINGLE-CHAIN T-CELL RECEPTORS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, no. 26, 20 December 1994 (1994-12-20), pages 12654 - 12658, XP002039051, ISSN: 0027-8424 * |
| ESHHAR Z ET AL: "SPECIFIC ACTIVATION AND TARGETING OF CYTOTOXIC LYMPHOCYTES THROUGH CHIMERIC SINGLE CHAINS CONSISTING OF ANTIBODY-BINDING DOMAINS AND THE GAMMA OR ZETA SUBUNITS OF THE IMMUNOGLOBULIN AND T-CELL RECEPTORS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, no. 2, 15 January 1993 (1993-01-15), pages 720 - 724, XP002009770, ISSN: 0027-8424 * |
| WEIJTENS ME, ET AL.: "A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes", GENE THERAPY, vol. 5, no. 9, September 1998 (1998-09-01), pages 1195 - 1203, XP000882695 * |
| WILLEMSEN RA, ET AL.: "Redirection of Human CTL by Chimeric T-Cell Receptors Specific for HLA-A1-Restricted, MAGE-1-Positive Melanoma Cells", NATURAL IMMUNITY, vol. 14, November 1995 (1995-11-01), pages 93, XP000882655 * |
Cited By (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100388942B1 (en) * | 2000-07-08 | 2003-06-25 | 한화석유화학 주식회사 | A Single Chain Variable Fragment of an Antibody for Protein Expressed on Cell Surface of Human Cortical Thymocyte and Leukemic Cell |
| WO2002013861A2 (en) * | 2000-08-11 | 2002-02-21 | Favrille, Inc. | Method and composition for altering a t cell mediated pathology |
| WO2002013861A3 (en) * | 2000-08-11 | 2002-12-05 | Favrille Inc | Method and composition for altering a t cell mediated pathology |
| WO2002077029A3 (en) * | 2000-11-07 | 2003-05-30 | Hope City | Cd19-specific redirected immune cells |
| WO2002077029A2 (en) * | 2000-11-07 | 2002-10-03 | City Of Hope | Cd19-specific redirected immune cells |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7265209B2 (en) | 2001-04-11 | 2007-09-04 | City Of Hope | CE7-specific chimeric T cell receptor |
| US7354762B2 (en) | 2001-04-11 | 2008-04-08 | City Of Hope | Method for producing CE7-specific redirected immune cells |
| US7446191B2 (en) | 2001-04-11 | 2008-11-04 | City Of Hope | DNA construct encoding CE7-specific chimeric T cell receptor |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| WO2004033685A1 (en) * | 2002-10-09 | 2004-04-22 | Avidex Ltd | Single chain recombinant t cell receptors |
| WO2004056845A2 (en) * | 2002-12-19 | 2004-07-08 | Johannes Gutenberg-Universität Mainz | Method for the production of a t cell receptor (tcr) consisting of a single chain tcr (sctcr) and a tcr constant region |
| WO2004056845A3 (en) * | 2002-12-19 | 2004-08-26 | Univ Mainz Johannes Gutenberg | Method for the production of a t cell receptor (tcr) consisting of a single chain tcr (sctcr) and a tcr constant region |
| US10336804B2 (en) | 2004-09-24 | 2019-07-02 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| US11208454B2 (en) | 2004-09-24 | 2021-12-28 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| US11858976B2 (en) | 2004-09-24 | 2024-01-02 | The Trustees Of Dartmouth College | Nucleic acid constructs encoding chimeric NK receptor, cells containing, and therapeutic use thereof |
| WO2007073147A1 (en) * | 2005-12-20 | 2007-06-28 | Erasmus University Medical Center Rotterdam | Apoptosis-inducing protein complexes and therapeutic use thereof |
| EP3097923A1 (en) | 2007-01-31 | 2016-11-30 | Yeda Research And Development Co., Ltd. | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| US9938497B2 (en) | 2009-10-29 | 2018-04-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US10689616B1 (en) | 2009-10-29 | 2020-06-23 | The Trustees Of Dartmouth College | T-cell receptor-deficient t cell compositions |
| US9663763B2 (en) | 2009-10-29 | 2017-05-30 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| US11834676B2 (en) | 2009-10-29 | 2023-12-05 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US10689619B2 (en) | 2009-10-29 | 2020-06-23 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US9822340B1 (en) | 2009-10-29 | 2017-11-21 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| US9821011B1 (en) | 2009-10-29 | 2017-11-21 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US10689617B1 (en) | 2009-10-29 | 2020-06-23 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| US11136549B2 (en) | 2009-10-29 | 2021-10-05 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| US10689618B2 (en) | 2009-10-29 | 2020-06-23 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US9957480B2 (en) | 2009-10-29 | 2018-05-01 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| WO2011140170A1 (en) * | 2010-05-04 | 2011-11-10 | Yeda Research And Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
| US9623049B2 (en) | 2010-05-04 | 2017-04-18 | Yeda Research And Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| US11872248B2 (en) | 2011-08-31 | 2024-01-16 | The Trustees Of Dartmouth College | Nucleic acids encoding chimeric receptor comprising NKP30 receptor and CD28 and CD3 zeta domains and human T cell containing |
| US10682378B2 (en) | 2011-08-31 | 2020-06-16 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| EP3392270A1 (en) * | 2011-09-15 | 2018-10-24 | The United States of America, as Represented by the Secretary Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| CN103974974A (en) * | 2011-09-15 | 2014-08-06 | 美国卫生和人力服务部 | T cell receptors recognizing HLA-A1- or HLA-CW7-restricted MAGE |
| WO2013039889A1 (en) * | 2011-09-15 | 2013-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| EP3766896A1 (en) * | 2011-09-15 | 2021-01-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| US11306131B2 (en) | 2011-09-15 | 2022-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing HLA-A1- or HLA-CW7-restricted mage |
| JP2020058354A (en) * | 2011-09-29 | 2020-04-16 | エーピーオー‐ティー ビー．ヴイ． | Multiple specific binding molecule whose target is abnormal cell |
| JP2018046811A (en) * | 2011-09-29 | 2018-03-29 | エーピーオー‐ティー ビー．ヴイ． | Multispecific binding molecules targeting aberrant cells |
| US11098115B2 (en) | 2011-09-29 | 2021-08-24 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| US10946104B2 (en) | 2012-01-13 | 2021-03-16 | Apo-Tb.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| US11034766B2 (en) | 2012-05-07 | 2021-06-15 | Trustees Of Dartmouth College | Anti-B7-H6 antibody, fusion proteins, and methods of using the same |
| US9790278B2 (en) | 2012-05-07 | 2017-10-17 | The Trustees Of Dartmouth College | Anti-B7-H6 antibody, fusion proteins, and methods of using the same |
| US11155786B2 (en) | 2015-01-23 | 2021-10-26 | Oslo Universitetssykehus Hf | Universal killer T-cell |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11717539B2 (en) | 2015-02-18 | 2023-08-08 | Enlivex Therapeutics RDO Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US10857181B2 (en) | 2015-04-21 | 2020-12-08 | Enlivex Therapeutics Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| US11883429B2 (en) | 2015-04-21 | 2024-01-30 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| US11241455B2 (en) | 2016-01-15 | 2022-02-08 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods of treating disease by metabolic control of T-cell differentiation |
| WO2017123808A1 (en) | 2016-01-15 | 2017-07-20 | The J. David Gladstone Institutes | Methods of treating disease by metabolic control of t-cell differentiation |
| US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2018132739A2 (en) | 2017-01-13 | 2018-07-19 | Agenus Inc. | T cell receptors that bind to ny-eso-1 and methods of use thereof |
| WO2019046856A1 (en) | 2017-09-04 | 2019-03-07 | Agenus Inc. | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
| CN107881185A (en) * | 2017-11-21 | 2018-04-06 | 重庆天科雅生物科技有限公司 | A kind of single-stranded TCR carrier Ts and single-stranded TCR T cells production technology |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2023047089A1 (en) | 2021-09-21 | 2023-03-30 | Oslo Universitetssykehus Hf | Binding proteins for terminal deoxynucleotidyl transferase (tdt) |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
Also Published As
| Publication number | Publication date |
|---|---|
| IL127142A0 (en) | 1999-09-22 |
| AU1292700A (en) | 2000-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000031239A1 (en) | Immune cells having predefined biological specificity, comprising chimeric t cell receptor | |
| US11325962B2 (en) | Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen | |
| Morgan et al. | High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens | |
| CN107428816B (en) | Combination T cell receptor gene therapy for cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 | |
| Zhao et al. | Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines | |
| EP2614151B1 (en) | Interleukin 15 as selectable marker for gene transfer in lymphocytes | |
| WO2016177339A1 (en) | T cell receptor for recognizing ny-eso-1 antigen short-chain polypeptide | |
| WO2017076308A1 (en) | Tcr for identifying ny-eso-1 antigen oligopeptide | |
| WO2005044996A2 (en) | Chimeric receptors with 4-1bb stimulatory signaling domain | |
| WO2016008973A1 (en) | Chimeric antigen receptor and its use | |
| US20100143315A1 (en) | Method for Improving the Specific Effector Function of Single-Chain Antigen-Recognizing Genetic Constructs (SCARC) Through Murinization Thereof | |
| CN111542545A (en) | CD38 directed chimeric antigen receptor constructs | |
| JP2021536266A (en) | Chimeric antigen receptor for solid cancer and T cells expressing chimeric antigen receptor | |
| WO2019182996A1 (en) | Antibody-interferon fusion proteins for enhancing adoptive t cell therapies for the treatment of cancer | |
| WO2016177195A1 (en) | T cell receptor for recognizing rhamm antigen short-chain polypeptide | |
| US20230321242A1 (en) | Chimeric antigen receptor (car)-expressing cells recognizing cea | |
| US11739136B2 (en) | Inducible dominant negative PD-1 and uses in adoptive cell therapy | |
| WO2018077242A1 (en) | T cell receptor for recognizing sage1 antigen short-chain polypeptide | |
| WO2023049803A1 (en) | Il5ra cell surface markers | |
| Willemsen | Genetic engineering of T cell specificity | |
| KR20240034205A (en) | An anti-EGFRviii antibody, a polypeptide, a cell expressing the polypeptide, a pharmaceutical composition containing the cell, a method for producing the cell, and a polynucleotide or vector containing a base sequence encoding the polypeptide. | |
| KR20240035506A (en) | A chimeric antigen receptor, a cell expressing the receptor, a pharmaceutical composition containing the cell, a method for producing the cell, and a polynucleotide or vector containing a base sequence encoding the chimeric antigen receptor. | |
| KR20240069766A (en) | IL5RA cell surface marker | |
| JP2024502170A (en) | Improved adoptive cell transfer therapy for cancer | |
| CN114286863A (en) | Bispecific chimeric antigen receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 12927 Kind code of ref document: A Format of ref document f/p: F |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN IL JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase |